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ABSTRACT
The total enantioselective and formal racemic syntheses of malbrancheamide B,
a bicyclo[2.2.2]diazaoctane-containing fungal metabolite are described. Over
seventy distinct [2.2.2]diazabicycles have been isolated from fungal sources
spanning three genii. This class of molecules displays remarkable structural
diversity and many members have demonstrated biological activity. Key to the
successful syntheses of malbrancheamide B was a novel domino reaction
sequence involving a 1-pot aldol condensation, alkene isomerization, and [4+2]
cycloaddition. In the case of the enantioselective synthesis, a chiral, nonracemic
aminal auxiliary on the diketopiperazine diene-precursor was used to direct facial
selectivity in Diels-Alder reaction.
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CHAPTER I
The BICYCLO[2.2.2]DIAZAOCTANE INDOLE ALKALOIDS
Introduction:
A number of prenylated indole alkaloids contain bicyclo[2.2.2]diazaoctane ring systems
at their core (Figure 1.1).1 This structural m otif was originally identified in the brevianamides in
19692 and isolation of similarly bicyclic metabolites from various aquatic and terrestrial species
of the Aspergillus, Penicillium, and Malbranchea genera continues today.

Despite similar

polycyclic skeletal structures, this family displays impressive structural diversity among its nearly
80 naturally occurring members (Figure 1.2).3

Genetic evidence and commonalities in core

structure and fungal source suggest that these metabolites share closely related biosynthetic
pathways.

While a great deal of insight into the biosynthetic relationships of the many

subfamilies has been gained over the last four decades, many details remain elusive and thus,
significant interest on the topic still exists. The core bicycle seen in all members of the family
has also drawn attention from the community of synthetic chemists. Multiple methodologies
for creating [2.2.2]diazabicycles have been developed and implemented in natural product total
syntheses. Presented here is a discussion of this family's general structural themes, synopses of
the isolation, bioactivities, and biosyntheses of each of the known subfamilies, and selected
total syntheses that highlight the unique methods by which the diazabicyclic core has been
Figure 1.1: Bicyclo[2.2.2]diazaoctane core
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Figure 1.2: Selected members of the brevianamide family
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constructed. Introduction and discussion of the malbrancheamides will be presented in a later
chapter.
Structural Themes:
This family of metabolites shares some key structural features in addition to the [2.2.2]diazabicycle.

Molecules of this family are biosynthetically derived from a two amino acids,

generally tryptophan and proline, and one or two isoprene units. Despite their common core
feature and their similar biosynthetic origins, alkaloids of this family demonstrate remarkable
structural variety. Members sharing the diazabicyclic core can differ in ring size, number, and
fusion pattern, in oxidation state, substitution patterns, and in the syn- or anti-relationship of
the diazaoctane bicycle (Figure 1.3). The numerous permutations coming from variations in all
these criteria help account for the diversity of observed metabolites.

Figure 1.3: Anti- and syn-diastereomers of the diazabicyclic core

a/?f/'-diastereomer

syn-diastereomer

The most visible variation among members of the family occurs in their ring systems.
Nearly all known examples contain 5-member pyrollidine ring attached to the diazabicycle.
Exceptions to this trend include the marcfortines which are biosynthetically related to pipecolic
acid and therefore contain the amino-acid's 6-member ring. Other variations in ring size can be
seen in differences between alkaloids with and without 7-member dioxepin rings in their
structure. The number of rings in the bicycles' polycyclic systems range from five to seven and
several ring fusion patterns are observed including spiro-oxindoles and spiro-indoxyls. Another
major distinction between subfamilies is the oxidation state of the diazabicyclic core.
3

Each

family of alkaloids exclusively contains either monoketopiperazine cores as in the
paraherquamides or diketopiperazines as in the brevianamides.

While all members of this alkaloid family contain the geminal dimethyl substitution
adjacent to the diazaoctane, other ring substitutions can occur. Brevianamides A and B, for
example, contain the common gem-dimethyl groups and indole oxidation, but no further
substituents.

The most notable case of substitution in this family is seen in the

malbrancheamides, which are unique in their indole halogenation.

The last noteworthy variable characteristic of this family is the stereochemical
configuration of the diazabicyclic core (Figure 1.3).

The majority of metabolites with this

diazaoctane bicycle feature the amide bridge syn to the C-19 proton (brevianamide numbering).
The relatively less common anti-configuration has so far been observed only in a few examples.
From a synthetic perspective, this feature poses the most interesting challenge. Replicating the
enantiomeric purity of such an unusual structure

necessitates the development of

stereoselective methodology.

The Brevianamides:
The brevianamide family of alkaloids was first isolated by Birch et al. from Penicillium
brevicompactum in 1969.2

Four of the six metabolites originally isolated in this study,

brevianamides A-D, were found to contain the novel bicyclo[2.2.2]diazaoctane core structure.
Eventually it was found that brevianamides C and D were artifacts of isolation resulting from
exposure to light, leaving brevianamides A and B as the sole brevianamide natural products
containing the unique core (Figure 1.2).4

Brevianamide A gained particular interest after it

demonstrated modest antifeedant and insecticidal effects.5 Over time, P. brevicompactum has

4

proven the most viable source for consistent isolation of brevianamides A and B, but P.
vindication has also been established as a source for brevianamide A.6

Structural elucidation revealed that these naturally occurring [2.2.2]diazabicycles consist
of diastereomeric hexacyclic ring systems.

They display very little substitution on their

polycyclic skeletal structures, lacking the proline or indole ring substituents observed on other
indole alkaloids of the family. They contain anti-configured bicyclic cores, a conformation that
has proven rare in the wake of subsequent isolation of numerous syn-configured diazabicycles.
Additionally, they contain a spiro-indoxyl moiety not observed in any of the other subfamilies of
alkaloids.

In order to probe the biosynthesis of these new alkaloids, Birch executed a series of
radiolabeled precursor incorporation studies shortly after the molecules' initial isolation.2,4 This
work identified tryptophan, proline, and mevalonic acid as the basic precursors of the
biosynthetic pathway in P. brevicompactum. Additionally, brevianamide F, the diketopiperazine
product of condensation between tryptophan and proline, also incorporated into brevianamide
A, suggesting that it was an intermediate along the biosynthetic pathway.

These findings

prompted Birch's proposal for the early biosynthesis of the brevianamides (Scheme 1.1).
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Scheme 1.1: Birch's early-stage biosynthesis o f brevianamide A
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Continuing research into the biosynthesis of the brevianamides was conducted by
Williams

and

coworkers

who

conducted

deoxybrevianamide E in P. brevicompactum.7

incorporation

studies

with

radiolabeled

In these studies it was determined that

deoxybrevianamide E was indeed a brevianamide A precursor, but that the [2.2.2]cycloadduct 1
was not. These observations led to the proposal that the [2.2.2]diazabicycle must not form until
after indole oxidation and pinacol shift, a conclusion that led to alternative biosynthetic pathway
proposals (Scheme 1.2). Synthetic obstacles have prevented the verification of any part of these
pathways at this time.

Scheme 1.2: Williams' alternative biosynthetic pathway proposals
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The M arcfortines:
Eleven years after the original isolation of the brevianamides, Polonsky et al. introduced
the next three [2.2.2]diazabicycles to the family of alkaloids, marcfortines A, B, and C (Figure
1.4).8 The marcfortines were isolated from a fungus used in the production of blue cheeses

6

which was then called Penicillium roqueforti.

Later this fungal species was reclassified and

subdivided into three distinct species, at which point it was found that only one of these, P.
paneum, produces the marcfortines.

Figure 1.4: Marcfortines A-C

marcfortine A

marcfortine B

marcfortine C

While these metabolites share the family's defining core characteristic, their structural
features distinguish them from the brevianamides. All three marcfortines contain heptacyclic
ring systems with syn-configured,

monoketopiperazine diazabicycles.

Instead of the

brevianamides' spiro-indoxyl moiety, the marcfortines contain spiro-oxindole skeletal fusion
patterns with C-6 and C-7 substituted indole rings that connect either dioxepin or pyran
moieties. The most unusual feature of these molecules is the six-membered, pipecolic acidderived ring rather than the 5-member, proline-derived ring displayed in nearly all other
[2.2.2]diazabicycles.

While the [2.2.2]diazaoctane bicycles that they share with the brevianamides suggest a
similar biosynthesis, the distinct structural characteristics, especially that of the pipecolic acid
ring, separate these alkaloids from those of the other subfamily. Biosynthetic investigation of

7

marcfortine A was first carried out by Kuo and coworkers.9 Their work showed, L-tryptophan, Lmethionine, L-lysine, and acetate as the biosynthetic precursors of the molecule, finding that
tryptophan incorporated into the spiro-oxindole, methionine contributed via SAM methylation,
lysine incorporated into the pipecolate, and acetate incorporated into the isoprene units.

The Paraherquamides:
The next major subfamily of [2.2.2]diazaoctane bicycles was discovered upon the
isolation of paraherquamide A from Penicillium paraherquei, also known as P. charlesii, in
1981.10 In the decades following the discovery of paraherquamide A, the paraherquamide
subfamily of alkaloids experienced substantial growth with the discovery and characterization of
some fifteen related molecules. Paraherquamides B-G were discovered next from P. charlesii,
and paraherquamides H and I were found together with a variety of similar metabolites (Figure
1.5) in cultures of either P. cluniae, Penicillium sp. IMI 332995, Aspergillus japonicas, P. charlesii,
or Aspergillus sp. IMI 337664.11 Like brevianamide A, a number of the paraherquamides display
biological activities. Paraherquamides A-G have demonstrated antinematodal properties, but
paraherquamide A remains the most notable for its anthelmintic activity against drug-resistant
parasites.12 Early results indicated that paraherquamide A's anthelmintic effectiveness against
nematodes with broad-spectrum drug resistance could lead to its use as a therapeutic, but it
was subsequently determined that its unacceptable toxicity levels make it unsuitable for such
use.13 Development of semisynthetic paraherquamide derivatives14 has successfully reduced
toxicity in mammals while maintaining effectiveness and has seen some use in combination
treatment in sheep.15

8

Figure 1.5: Selected members of the paraherquamide family of alkaloids
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Given the number of known paraherquamide metabolites, the structural diversity
evident in this subfamily of [2.2.2]diazabicycles is not surprising. Features conserved across this
family include syn-configured [2.2.2]diazabicyclic cores at the monoketopiperazine oxidation
state similar to those of the marcfortines.

Most paraherquamides also possess the same

tryptophan-derived spiro-oxindole and dioxepin rings seen in marcfortines A and B. Unlike the
previously discussed family members however, the paraherquamides are distinguished by
proline-derived rings, moieties upon which many different substitution patterns are observed,
including several methylation and oxidation patterns.

As with previous subfamilies, biosynthetic interest has revealed the elementary
components of these molecules. Through a series of feeding experiments with P. cf. canescens,
the Williams group has found that the synthesis of paraherquamide A in this species
9

incorporates L-isoleucine, 0-methyl-L-proline, L-methionine, and L-tryptophan.16

Further

feeding studies by this group went on to probe the incorporation of possible intermediates into
paraherquamide

A

by P.

cf.

canescens,17

This study

also found

that

synthetic

preparaherquamide 19 does incorporate into paraherquamide A, while the diketopiperazine
analog of preparaherquamide 19 does not. These results suggest that the tryptophan-derived
carbonyl is reduced to the monoketopiperazine before the [2.2.2]diazabicycle is formed and that
the key cyclization event must occur before dioxepin or spiro-oxindole formation (Scheme 1.3).

Scheme 1.3: P. cf. canescens incorporation study of preparaherquamide into paraherquamide A

O

The Stephacidins and Notoamides:
The first metabolite isolated from the next family of diazabicyclic indole alkaloids was
discovered in 1996 by Gloer and White from Aspergillus sclerotlorum (Figure 1.6).“

This

molecule, sclerotiamide A, was originally misclassified as a member of the paraherquamides due
to the skeletal features it shares with that family.

It was determined, however, that

sclerotiamide possesses a diketopiperazine core whereas all the paraherquamides contain
monoketopiperazines.

Thus,

structurally

distinct

from

the

monoketopiperazine

paraherquamides, the pipecolic acid-derived marcfortines, and the anti-configured

10

Figure 1.6: Sclerotiamide, stephacidins A and B, avrainvillamide, and notoamide B

HO
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HO
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brevianamides, sclerotiamide was correctly assessed as the first known member of a new family
of indole alkaloids. This family saw several major expansions, first in 1999 with the discovery of
the stephacidins A and B from Aspergillus ochraceus WC76466 by Bristol-Myers Squibb,19 then
with the isolation of avrainvillamide from Aspergillus sp. CNC358 by Fenical in the same year,20
and again in 2007 when the Tsukamoto group isolated notoamides A-D from Aspergillus sp.
MF297-2.21

With the addition of so many novel isolates, there was a corresponding growth in the
diversity of the family's structural characteristics (Figure 1.6). Sclerotiamide A, the first known
family member, is structurally defined by its syn-configured core bicyclo[2.2.2]diazaoctane, a
diketopiperazine core unit, spiro-oxindole and dioxepin rings, an unsubstituted proline ring, and
11

a unique C-10 hydroxyl substitution (paraherquamide numbering).

Stephacidin A, B, and

avrainvillamide in contrast, share these features, but lack the spiro-oxindole and hydroxyl
substituent.

While the differences in substitution and ring fusion patterns provide interesting points
of differentiation, it was not until the isolation of stephacidin A, notoamide B, and a novel
isolate, versicolamide B from new fungal sources, Aspergillus versicolor22 and Aspergillus sp.
MF297-223 respectively (Figure 1.7), that the subfamily's most interesting feature became
apparent. Characterization of these metabolites revealed that the stephacidin A and notoamide
B isolates of A. versicolor were structurally identically to the syn-configured alkaloids previously
seen and that versicolamide B displayed the comparatively rare anti-configuration which had
only been previously observed in the brevianamides. These stereochemical conclusions did not,
however, prove to be true for the isolates of Aspergillus sp. MF29702, which contained
diazabicyclic rings of the configuration opposite of their A. versicolor-derived analogs. Members
of this family do exhibit biological activities, although they are generally more moderate than
the antinematodal properties of the paraherquamides. Sclerotiamide proved to be effective in
killing Helicoverpa zea corn earworm larvae and inhibiting the growth of surviving larvae.18
Stephacidins A and B both proved cytotoxic to various human cell culture lines, although it was
proposed that the activity of the latter was the result of retrodimerization to form
avrainvillamide in vivo.19 Avrainvillamide was observed to inhibit the growth of multipleantibiotic-resistant strains of Staphylococcus aureus, Steptococcus pyogenes, and Enterococcus
feccalis21 and was proved cytotoxic to a variety of human cancer cell lines.20 Given the growing
problem of antibiotic resistance, avrainvillamide and its dimer stephacidin B pose interesting
candidates for further biological study.
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Figure 1.7: The stephacidin-type alkaloids isolated from specific fungal sources
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Extensive research into the biosynthetic origins of the stephacidin and notoamide family
of molecules has resulted in a proposal of a comprehensive biosynthesis of stephacidin A and
notoamide B (Scheme 1.4).24 The proposed biosynthesis of the stephacidin/notoamide family
begins with a precursor that intersects the early stages of the brevianamide synthesis. The
common precursor, brevianamide F, undergoes sequential prenylation, oxidation, and
isomerization until it forms the requisite achiral azadiene precursor of both enantiomeric series
of natural products. At this point, enantioselective intramolecular hetero-Diels-Alder
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Scheme 1.4: Proposed biosynthesis of stephacidin A and notoamide B
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establishes the bicyclo[2.2.2]diazaoctane. The absolute conformation of the resulting products
depend upon the fungal species in question, with either the syn- or anti-conformation created
exclusively in each organism. The resulting cycloadduct can then undergo oxidative cyclization
to form stephacidin A, which can in turn undergo oxidative pinacol rearrangement to notoamide
B.

The Asperparalines:
Asperparaline A was first isolated one year after sclerotiamide by Hayashi and
coworkers from what was then known as Aspergillus japaconis JV-23.25 This species was later
divided into seven species, only two o f which, A. aculeatinus and A. fijiensis, were shown to be
produce the diazabicyclic indole alkaloid.26 In a 2000 journal entry, Hayashi et al. reported the
isolation of asperparalines B and C from the same fungal source that yielded asperparaline A.27
All of these alkaloids have demonstrated paralytic effects in silkworms and asperparaline A has
also shown anthelmintic activity against Trichostrongylus colubriformis in gerbils.25,27,28 The
mechanism of silkworm paralysis by asperparaline A was further investigated by Hayashi et al.
and was found to involve the molecules effect as a non-competitive antagonist of nicotinic
acetylcholine receptors in silkworm neurons.29 In a subsequent publication by Everett and
coworkers, the isolation of asperparaline A and a new asperparaline A-derivative, SB202327
were reported from Aspergillus fijiensis.11*

Structurally, the four asperparalines are very similar (Figure 1.8). All four asperparalines
contain syn-configured diazabicycles at the monoketopiperazine oxidation state. They each
contain 5-member proline-derived rings which may unsubstituted, as in the case of
asperparaline C, or display either methylation or oxidation. These molecules are distinguished

15

from other [2.2.2]diazaoctane alkaloid families by their 3-spiro-succinimide ring systems. This
feature is unique to the asperparaline subfamily of alkaloids.

Figure 1.8: The asperparaline family of indole alkaloids

V

M
e

asperparaline A

asperparaline B
V

V Me

'Me
O

asperparaline C

O
SB202327

Given the skeletal similarities between the asperparalines and paraherquamides, the
Williams group was motivated to perform precursor feeding studies aimed at elucidating the
biosynthetic pathway of asperparaline A.30 These results showed that despite its appearance to
the contrary, asperparaline A incorporates not only tryptophan, but all the same basic units as
paraherquamide

A.

This observation,

together with

the

subsequent

detection

of

preparaherquamide in A. aculeatinus, suggest that the biosynthesis of paraherquamide A and
asperparaline A are unified at least up until preparaherquamide at which point the imide moiety
of the asperparalines is likely the product of degradation of the paraherquamide indole nucleus
(Scheme 1.5).111

Chrysogenamide A:
Chrysogenamide A, the only known member of the chrysogenamide family, was first
isolated from Penicillium chrysogenum No. 005 by Zhu and coworkers in 2008 during screening
for molecules with neuroprotective activity.31 Structurally, this alkaloid very closely resembles
16

Scheme 1.5: Proposed unified synthesis of asperparaline A and paraherquamide A
c o 2h

NH.
OH

NH

OPP

V 'M
e

OH

the marcfortines. It contains an anti-configured [2.2.2]diazabicycle at the monoketopiperazine
oxidation state, a methylated pipecolic acid ring much like that of the marcfortines, a spirooxindole ring fusion pattern, and a isoprene substitution at the indole's C-7 position. Little is
known about the biosynthesis of this compound, while its structural similarities to the
marcfortines suggest related biosynthesis, the o/it/-configured diazabicycle could indicate a
distinct pathway.

Figure 1.9: Chrysogenamide A

NH

chrysogenamide A
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Previous Synthetic Methods:
While not every indole alkaloid has been the target of a total synthesis, numerous
syntheses of select diazabicycles have been completed. From these efforts have emerged five
distinct methods for establishing the natural products' core structural feature.

Syntheses

representative of each method are presented here as an introduction to these strategies.

Intram olecular SN2' Cyclization:

The first synthetic methodology used to establish the bicyclo[2.2.2]diazaoctane core was
not performed in the context of a total synthesis until nearly two decades after the original
isolation of the brevianamides. The Williams group developed an intramolecular SN2' cyclization
pathway in the synthesis of brevianamide B ( l) 32, but later adapted its use for the syntheses of
several other indole alkaloids.33 The key cyclization event of these syntheses involves a
diketopiperazine precursor that undergoes enolization and intramolecular nucleophilic attack on
its allylic halide in an SN2' fashion (Scheme 1.6). This methodology was employed with great
success in the Williams' brevianamide B synthesis which proved significant in that it represents
the first synthesis of a diazabicyclic indole alkaloid.

Scheme 1.6: Intramolecular SN2' cyclization
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NPMB
O
XCI
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The Williams brevianamide synthesis began with allylated proline derivate 2 (Scheme
1.7).32 Nucleophilic ring opening of this substrate with p-methoxybenzylamine yielded protected
amide 3.

PMB-protected amide 3 was then converted to diketopiperazine 4 via secondary

amine acylation and subsequent ring closure. Ozonolysis of 4 resulted in oxidative cleavage of
the allylic olefin to aldehyde 5. Wittig olefination of 5 followed by sodium borohydride

Scheme 1.7: Synthesis of a SN2' precursor in the Williams synthesis of brevianamide B
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NPMB

NPMB

reduction of the resulting a,£-unsaturated aldehyde gave primary alcohol 6. Silyl protection of
allylic alcohol 6 with TBSCI allowed for diketopiperazine deprotonation and formation of methyl
ester 7 after quenching with methyl chloroformate. Coupling of the mixture of diastereomers in
methyl ester 7 with gramine yielded 8. A four step-sequence then removed the methyl ester
group of 8, converted its silyl-protected primary alcohol to an analogous primary halide, and
Boc-protected the gramine to give 9. The formation of this allylic halide precursor was crucial to
the synthesis.

The creation of this molecule allowed for the planned intramolecular SN2'

cyclization event that established the bicyclic core structure of the target alkaloid.

The key intramolecular SN2' cyclization step of the brevianamide B synthesis was first
attempted with the treatment of precursor 9 with NaH in DMF at room temperature (Table 1.1).
This reaction gave bicycles 10 and 11 as a 2:1 mixture of diastereomers in 62% combined yield.

Table 1.1: Intramolecular SN2' cyclizations of precursor 9
Cl

NPMB

Boc

BBfiEBI

ESQRH
BHh

2:1

62%

NaH in DMF at 100°C

3:97

82%

NaH, 18-crown-6 in DMF at rt

4:1

56%

i

NaH in DMF at rt

2
3
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Interestingly, when the reaction was repeated in benzene at 100°C the epimeric ratio of 10:11
reversed its preference to 3:97 in 82% combined yield. Desiring an enhanced preference for the
ont/-configuration characteristic of the target alkaloid, further trials were conducted and it was
found that exposing 9 to NaH and l8-crown-6 in DMF gives a 4:1 ratio of 10 to 11 in 56%
combined yield.

Satisfied with the selectivity and yield of the SN2' cyclization for the anti-configured
diazabicycle, synthetic effort turned to forming the spiro-indoxyl moiety of the targeted
metabolite.

The ont/'-configured [2.2.2]diazabicyclic 10 was exposed to concentrated HCI

affecting indole deprotection and olefin-cation cyclization (Scheme 1.8). Hexacyclic 12 was then
converted to the corresponding indoxyl 13 via mCPBA treatment followed by exposure to
NaOMe. After standard oxidative deprotection strategies failed to remove the PMB-group it
was found that deprotonation with tBuLi followed by quenching and molecular oxygen
respectively gave the final product, brevianamide B (1).

Scheme 1.8: Completion of the brevianamide B synthesis
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R = PMB

The completion of the synthesis of this fungal metabolite proved interesting in multiple
ways. The structural characterization of synthetic brevianamide B allowed for the confirmation
of the proposed structure for the original isolate. The development of both syn- and antiselective SN2 cyclization methodologies allowed access to structural cores of indole alkaloids of
both configurations. The SN2' cyclizations used in Williams' later [2.2.2]diazabicycle syntheses
also gave improved yields and were exclusively selective for the syn-diastereomer (Scheme
1.9).33

Scheme 1.9: SN2' cyclizations toward paraherquamide B and the stephacidins
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Biom im etic Intram olecular Hetero D iels-Alder Reaction:
As originally proposed by Porter and Sammes one year after the first isolation of
brevianamide B, the biosynthetic formation of the [2.2.2]diazabicyclic core in this family of
indole alkaloids is believed to occur via intramolecular hetero Diels-Alder (IMDA) reaction.34
The proposed IMDA of a 5-hydroxypyrazine-2(lH)-one would provide a powerful and elegant
means of establishing the desired core structure with simultaneous formation of two bonds
(Scheme 1.10).

The Williams group executed a second synthesis of brevianamide B

incorporating the IMDA cyclization instead of their previously developed intramolecular SN2'
cyclization methodology.35

Scheme 1.10: Intramolecular hetero Diels-Alder of a 5-hydroxypyrazine-2(lH)-one

OH
OH

brevianamide A

The

Williams
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IMDA
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synthesis

began

with

epi-

deoxybrevianamide E (14) (Scheme 1.11). Conversion of 14 to its analogous diketopiperazine
diene precursor proceeded in only two steps. First the diketopiperazine secondary amide was

Scheme 1.11: Synthesis of an IMDA precursor
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converted to its lactim ether 15.

Lactim ether 15 was then oxidized with DDQ to IMDA

precursor 16. Exposure of precursor 16 to aqueous KOH resulted in olefin isomerization to
intermediate azadiene 17 which immediately underwent [4+2] cycloaddition with the readily
accessible exocyclic alkene (Scheme 1.12). In this system, IMDA led to a 2:1 mixture of the
undesired syn-diastereomer 18 and the o/it/'-diastereomer 19 with a combined yield of 60%. The
desired minor product of this cyclization (19) was then quantitatively oxidized to its
corresponding hydroxyindolenine 20.

Finally, pinacol rearrangement and lactim ether

deprotection affected the desired transformation of 20 to (±)-brevianamide B (1).

Scheme 1.12: IMDA and endgame for brevianamide B synthesis
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The incorporation of an IMDA in the synthesis of brevianamide B marked the first use of
the biomimetic reaction in the total synthesis of a natural product. While a complete total
synthesis supported the possibility for a biosynthetic IMDA, the poor stereoselectivity during the
cycloaddition and the necessarily racemic reaction products posed an obvious drawback of the
24

approach. One noteworthy variation on this methodology was developed as an alternative to
the basic conditions used by Williams in the brevianamide synthesis. Liebscher and coworkers
pioneered alternative reaction conditions for accessing the [2.2.2]diazabicycle that involved
neutral conditions (Scheme 1.13).36 Basic and neutral IMDA reactions have since been used in a
number of natural product total syntheses.37

Scheme 1.13: Liebscher's IMDA study
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Oxidative Enolate Coupling Reaction:
After a successful series of investigations into the reactivity of enolated carbonyl
functionalities with heterocyclic aromatic rings exposed to metal oxidants like Cu(ll), the Baran
group demonstrated the potential utility of these developments in the syntheses of
[2.2.2]diazabicyclic alkaloids.38

In 2006, the Baran group reported the most recent total

synthesis of stephacidin A (21) that incorporated their new oxidative enolate coupling method
for creating [2.2.2]diazabicycles.39 This enantioselective ring formation effectively applied their
oxidative coupling while providing improved synthetic yield o f the diazabicyclic target and
involved the intramolecular oxidative coupling of ester and amide enolates (Scheme 1.14). They
predicted that the close proximity of sp2-hybridized a-carbons in the metal-bound transition
state would drive reactivity and that the quaternary stereocenter of the proline ring would
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contribute to facial selectivity of bond formation.

In this manner, they achieved a highly

selective synthesis of the natural product.

Scheme 1.14: Model oxidative enolate coupling to form [2.2.2]diazaoctane bicycles

Extensive effort led to the preparation of tryptophan and proline derived starting
materials, 22 and 23 (Scheme 1.15). With both amino acid-derived components necessary for
the stephacidin synthesis on-hand, reductive deprotection of the carboxybenzyl (Cbz) protecting
group in 23 with palladium on carbon revealed proline methyl ester 24. Immediate exposure of
24 to 22 with HATU allowed peptide coupling and prevented formation of the y-lactam
corresponding to 24. Resulting amide 25 then underwent chemoselective Cbz deprotection,
diketopiperazine ring closure, and /V-methoxymethyl (MOM) protection of the ring-closed
secondary amide functionality. MOM-protected amide 26 was deemed an appropriate starting
material for the key synthetic step and screening revealed Fe(acac)3 as the most effective metal
oxidant for the reaction. Enolation of 26 with LDA and exposure to Fe(acac)3 provided 27 as a
single diastereomer in 61% yield.

Having successfully executed the stereoselective

intramolecular oxidative enolate coupling to form the alkaloid's core [2.2.2]diazabicycle, the
synthesis o f stephacidin A only required a few more transformations. Coupling product 27 was
MOM-deprotected, excess methyl Grignard converted the exocyclic methyl ester to a tertiary
alcohol, and the alcohol intermediate was dehydrated to the corresponding alkene. Because
instability of 28 under acidic conditions precluded Friedel-Crafts alkylation, sulfolane was used
to facilitate thermolytic Boc deprotection and ring closure to form 21 in modest yield.
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Scheme 1.15: Completion of stephacidin A
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Aminoacyl Radical Cyclization:
In their synthesis of avrainvillamide (29) and stephacidin B (30) the Myers group applied
an aminoacyl radical cyclization to form the alkaloid core structure.40 The application of this
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new approach marked the use of the fourth unique method for forming [2.2.2]diazabicycles in
total syntheses. In synthesizing monomeric avrainvillamide, they also showed the ease with
which 29 dimerizes to stephacidin B (30) in mild conditions.

The Myers synthesis began with cyclohexanone 31, a structure synthesized in two steps
from commercially available materials (Scheme 1.16). Cyclohexanone 31 was deprotonated,
facilitating the diastereoselective addition of novel electrophile 32 to the resulting enolate.
Coupling product 33 was then converted to /V-Boc amino nitrile 34 through Strecker-like
addition of hydrogen cyanide with reasonable diastereoselectivity. The a-carbon of ketone 34
was epimerized by deprotonation with KHMDS in order to install the necessary stereochemistry
of the target alkaloids and platinum catalyst 35 was used to convert 34's nitrile moiety to a
primary amide. Thiophenol and triethylamine treatment of resulting primary amide 36 led to
conjugate thiophenol addition as well as cyclic hemiaminal formation. Spirocyclic 37 was then
dehydrated and its N-Boc protecting group was cleaved.

Subsequent acylation of the

deprotected pyrolidinyl amino group with radical precursor 38 produced amide 39. At this point
amide 39 featured both a radical initiator and terminator in such a way that it could undergo the
envisioned radical cyclization. Heating of amide 39 with tert-amyl peroxybenzoate in tert-butyl
benzene resulted in homolytic bond cleavage to form aminoacyl radical intermediate 40. The
radical formed in this homolytic cleavage quickly attacks the more substituted constituent of the
enamide C-C double bond before it is finally trapped with the expulsion of the thiophenol radical
acceptor. Radical cyclization gives [2.2.2]diazabicyclic avrainvillamide-precursor 41, for which
transformation to the natural product proved relatively simple. 41 was converted to a-
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Scheme 1.16: Synthesis of avrainvillamide
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iodoenone 42 in three steps.

Following these manipulations, a-iodoenone 42 underwent

Ullman-like coupling with aryl iodide 43 to give nitroarene product 44. Reduction of 44 with
activated zinc powder yielded the first synthetic target (-)-29, which could be easily converted to
(+)-stephacidin B (30) in the presence of triethylamine.

Cation Olefin Cyclization:
The Simpkins lab employed a novel method for establishing [2.2.2)diazabicycles in a
series of total syntheses including that of brevianamide B.41 The Simpkins' cation cascade
sequence for creating the alkaloids' bridged diketopiperazine cores was envisioned to initiate via
cation formation of an appropriately substituted DKP (Scheme 1.17). Prenyl trapping of the
cation would result in bicyclo[2.2.2]diazaoctane core formation and would allow a second
cyclization with the indole ring. This method promised a succinct means for accessing two rings
of the indole alkaloids' core structure in a single operation.

Scheme 1.17: Cation olefin cascade cyclization
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The Simpkins synthesis of brevianamide B began with the coupling of prenylated proline
45 to indole pyruvic acid 46 (Scheme 1.18).

Hydroxy-DKP 47 then underwent cation olefin

30

cyclization to establish both the bridged DKP core and adjacent gem-dimethyl 6-member ring of
the diastereomeric products 48a and 48b. This reaction was observed with only moderate
selectivity, giving a 4:1 ratio of epimers. It was hypothesized, but never investigated in this
system, that more sterically bulky amide protecting groups would impart a stronger facial bias.
The minor diastereomer, 48b, which corresponded to the bicyclic core of brevianamide B was
then isolated and underwent a two-step sequence of peracid oxidation and base-catalyzed
rearrangement to spiro-indoxyl bridged DKP 49b. Deprotection of 49b via reductive cleavage
with Sml^LiCI led to problematic over-reduction of the indoxyl moiety, which then required
oxidation with Dess-Martin periodinane to establish the target, brevianamide B (1). While the
selectivity in this synthesis was moderate and favored the undesired diastereomeric bicycle, it
did demonstrate a strong step-wise efficiency.
Scheme 1.18: Simpkins' synthesis of brevianamide B
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CHAPTER II

DEVELOPMENT OF DOMINO REACTION SEQUENCE
Introduction and Retrosynthesis:
The primary goal of our initial studies was to develop a general and stereoselective
method for establishing bicyclo[2.2.2]diazaoctane cores that could be applied to multiple
targets.

We chose to pursue a diastereoselective intramolecular hetero-Diels-Alder (IMDA)

because of the existing methods for forming the core structure, we were most impressed by
Williams' IMDA.1 The Williams' IMDA had proven elegant in its powerful, concerted bond
formation and so our main challenge would be to devise a method with which to execute the
reaction stereoselectively.
As demonstrated in both the previously discussed brevianamide synthesis13 and a
subsequent synthesis of stephacidin A (l),2f the reactive diketopiperazine (DKP) azadienes
involved in the key [4+2] cycloadditions of these syntheses and nearly all of Williams' other
syntheses are achiral (Scheme 2.1). Achirality in the intramolecular reaction of prestephacidin 2
necessarily leads to a racemic mixture of cycloadducts (i)-stephacidin A (1) and its epimer, (±)Scheme 2.1: Racemic IMDA in synthesis of stephacidin A
OH
achiral DKP
azadiene

OH
NH

OR

OR

OH

d r 2.1:1

OH

(+)-C6-ep/-stephacidin (3)

(+)-stephacidin A (1)
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C6-ep/-stephacidin (3). These epimeric cycloadducts were isolated in a 2.1:1 diastereomeric
ratio representative of similar achiral IMDA reactions. While biosynthetic studies suggest that
achiral precursors are consistent with natural alkaloid biosyntheses, a weak diastereomeric ratio
is not representative of the single enantiomeric series with which these metabolites are
produced in nature. From a synthetic perspective, this suggests that by adhering closely to the
presumed biosynthetic pathway, we may limit the potential to make [2.2.2]diazabicycles
stereoselectively.
In contrast to the numerous racemic syntheses which involved achiral intermediates,
Williams and coworkers also conducted asymmetric biomimetic IMDA syntheses of VM55599lc
and versicolamide B.1'

Unlike the precursors of related alkaloids, the reactive azadiene

intermediates of the VM55599 and versicolamide B syntheses possess chiral centers at their
spiro-oxindole and proline ring moieties respectively. The IMDA of versicolamide B precursor
gave a racemic mixture of cycloadducts with a diastereomeric ratio of 1.4:1, suggesting that
chirality at the spiro-oxindole functionality exerts little effect on facial preference of the IMDA.
In contrast, the IMDA of VM55599 did demonstrate more reasonable facial preference with a
diastereomeric ratio of 7.3:2.0, supporting the idea that chiral proline substituents could restrict
access of a single azadiene face;
Previous work in the Scheerer research group has also probed the effect of chiral
azadienes on the diastereoselectivity of the IMDA.

In this investigation researchers

characterized the thermal, intermolecular Diels-Alder cycloadditions of a readily prepared
chiral, nonracemic DKP diene (4) with a variety of dieneophiles (Scheme 2.2).2 Azadiene 4 was
synthesized in five steps from L-serineand featured a chiral t-butyl aminal. This sterically bulky
aminal proved very effective in exerting diastereofacial control over the cycloaddition and could
be removed following cyclization. In addition to the clear facial bias, cycloadditions of 4
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Scheme 2.2: Diels-Alder cycloaddition of a chiral, non-racemic DKP diene
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NY
MeO

^
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R3

M+2]

MeO

*4

revealed a modest preference for the endo transition state and predictable regiochemistry with
electron-rich or electron-deficient dienophiles, despite the dissonant charge affinity pattern of
the azadiene. This predictable direction and subsequent cleavage encouraged the use of
similarly bulky, removable substrates in our synthetic endeavors.
Interested in adapting our methodology to a targeted synthesis, we envisioned the
IMDA of a possible malbrancheamide precursor 5 (Scheme 2.3).3

As in the previous

intermolecular, chiral DKP Diels-Alder cycloadditions, we anticipated that the chiral aminal
could effectively hinder one face of the diketopiperazine and drive dieneophile to approach
exclusively to the opposite ring face during [4+2] cycloaddition. Although we still expected the
Scheme 2.3: Directed IMDA of chiral DKP azadiene 5

chiral DKP
azadiene
NBOM
Cl
BOM
j f 4 +27

I [4+21

BOM

R

R

(+)-C6-epi- pre-malbrancheamide (7)

(+)-pre-malbrancheamide (6)
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formation of a C6-epimer (7) of our desired cycloadduct (6), we were curious to see which, how
many, and in what diastereomeric ratio this reaction's cycloadducts would form.
Our initial model study focused on exploring the possibility of directed intramolecular
hetero-Diels-Alder reactions of DKP-derived azadienes not necessarily related to natural
products.

Based

on

the

numerous

examples

of

syntheses

and

biosynthesis

of

[2.2.2]diazabicycles, we recognized that the model IMDA precursor analogue of 5 must contain a
chiral, non-racemic DKP azadiene coupled to an aromatic ring substituted with an alkene
dieneophile. Fortunately, DKPs 8 and 9, formed in the same process as DKP-derived azadiene 4,
and aromatic aldehyde 10 were easily prepared.

While the t-butyl analog of 8 had been

synthesized previously as a precursor to 4 and could have been used in this model reaction,
difficulty in removal of the t-butyl group via acidic aminal hydrolysis in previous studies
motivated the use of an alternative directing functionality. We anticipated the steric hindrance
exerted by DKP diene-precursor 8's phenyfaminal to be comparable to that of the t-butyl aminal
and valued the option to remove the phenyl directing group from our IMDA cycloadduct via
reductive methods.

We envisioned that the aldol condensation of 8 and 10 would afford

coupling product 11 (Scheme 2.4).

The isomerization of 11 under basic conditions would

generate the azadiene intermediate 12, which would rapidly undergo IMDA. We hoped this
synthetic

sequence would

generate

model

target

[2.2.2]diazabicycle

18 with

good

diastereofacial selectivity and yield. We chose to conduct our model study with DKP 8 due to
the abundance of this material over its epimer 9.
M ethods and Results:
We began our model study with the preparation of DKP-lactim ether 8 in an analogous
fashion to the synthesis of azadiene 4 (Scheme 2.5). /V-chloroacyl L-serine methyl ester was
added to benzaldehyde dimethyl acetal with p-toluenesulfonic acid monohydrate to install the
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Scheme 2.4: Model Retrosynthesis for bicyclo[2.2.2]diazaoctane core
Ph

Ph

Ph
13
0
OMe

Ph
CHO

10

+

MeO
phenyl aminal auxiliary. Subsequent treatment with sodium azide led to halide displacement
and the resulting intermediate azide underwent Staudinger reduction with resin-bound
phosphine to afford diastereomeric cyclized products 8 and 9 in 36% and 19% yield,
respectively.

^
'Scheme 2.5: Synthesis of DKP azadiene-precursors 8 and 9
1. PhCH(OMe)2,
TsOH, PhMee ’
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H
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N

3. PPh3 resin,
PhMe, 90°C
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(yield of 3 steps)

H
8
36%

MeO
9
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The aromatic aldehyde 10 was easily prepared upon completion of 8. It was quickly
recognized that a so called "domino" sequence of the desired transformations was occurring
under a single set of conditions (Scheme 2.6). When left to reflux under basic conditions for 24
hours, DKP 8 and salicylic aldehdye 10 yielded [2.2.2]diazabicycle 13 in good yield (76%) and
with excellent diastereoselectivity (dr 95:5).
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X-ray crystallographic analysis revealed the

absolute configuration of this molecule/ confirming the facial preference of the azadiene to
engage the ring face opposite the phenyl aminal in cycloaddition.
Scheme 2.6: Domino reaction sequence
H Ph
Ph

.OMe

NaOMe
MeOH

CHO
+

65°C
MeO
aldol condensation

76% yield
dr 95:5

Ph
Ph
H
OMe

alkene
isomerization
OMe

To achieve this domino reaction sequence, basic conditions first affected enolization of
the amide functionality of DKP 8, allowing aldol addition and condensation to intermediate 11.
The same basic conditions then caused alkene isomerization to reactive azadiene 12 which
underwent thermal IMDA cycloaddition. Satisfied with the yield, diastereomeric ratio, and ease
of operation of our model synthesis, we shifted our synthetic efforts toward the natural
product, malbrancheamide B.
In summary, we successfully employed a novel diaStereofacially selective IMDA
cycloaddition in the synthesis o f a model [2.2.2]diazaoctane bicycle. The originally envisioned
two-step, three-transformation model sequence was found to instead occur in a single pot with
good yield (76%) and excellent diastereoselectivity (95:5).

We attribute the observed

diastereofacial bias to a non-racemic, chiral phenyl aminal auxiliary on the DKP-derived azadiene
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component of the [4+2]. Pleased with the reliable reactivity and selectivity, we next set out to
adapt this reaction sequence to the total synthesis of malbrancheamide B.
Experimental Section:
General Information. All reactions were carried out under an atmosphere of nitrogen in flamedried or oven-dried glassware with magnetic stirring unless otherwise indicated. Acetonitrile,
THF, toluene, and Et20 were degassed with argon and purified by passage through a column of
molecular sieves and a bed of activated alumina.4 Dichloromethane was distilled from CaH2
prior to use.

All reagents were used as received unless otherwise noted.

Flash column

chromatography5 was performed using SiliCycle siliaflash P60 silica gel (230-400 mesh).
Analytical thin layer chromatography was performed on SiliCycle 60A glass plates. Visualization
was accomplished with UV light, anisaldehyde, eerie ammonium molybdate (CAM), potassium
permanganate, or ninhydrin, followed by heating. Film (or KBr pellet) infrared spectra were
recorded using FTIR spectrophotometer.

Optical rotations were determined by digital

polarimeter at 25 °C. 1H NMR spectra were recorded on a 400 MHz spectrometer and are
reported in ppm using solvent as an internal standard (CDCI3 at 7.26 ppm) or tetramethylsilane
(0.00 ppm). Proton-decoupled 13C-NMR spectra were recorded at 100 MHz spectrometer and
are reported in ppm using solvent as an internal standard (CDCI3 at 77.00 ppm). All compounds
were judged to be homogeneous (>95% purity) by *H and 13C NMR spectroscopy unless
otherwise noted as mixtures.

Mass spectra data analysis was obtained through positive

electrospray ionization (ICR-MS w / NaCI).

HPLC was performed using a binary gradient

(acetonitrile, water with 0.1% TFA) and peak detection was accomplished with photodiode
array.
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Experimental Procedures.

0

Ck

X

1. PhCH(OME)2,
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2. NaN3) 80°C
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PhMe, 90°C
(yield o f 3 steps)
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8
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9
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Diketopiperazine tactim methyl ether 8, 9. To /V-chloroacyl L-serine methyl ester6 (4.5 g, 22.8
mmol) in toluene (220 mL) at rt was added benzaldehyde dimethyl acetal (2.9 ml, 27.4 mmol)
and p-toluenesulfonic acid monohydrate (108 mg, 0.57 mmol). The solution was heated at reflux
for 16 h with a Dean-Stark trap. After cooling to rt, the solution was diluted with saturated
aqueous NaHC03 (2 x 50 ml). The organic layer was removed and the aqueous portion extracted
with Et20 (75 ml). The combined organic layers were washed with brine (50 ml), dried with
Na2S04, and concentrated in vacuo. The viscous product was purified by flash column
chromatography on silica gel (elution: 10% to 60% EtOAc in hexane) to afford a yellow oil (5.48
g, 19.23 mmol, dr ca. 2:1). This intermediate product was dissolved in butanone (110 ml),
sodium azide (2.50 g, 38.5 mmol) was added, and the heterogenous mixture was heated to 80
°C for 15 h. After cooling to rt, the mixture was concentrated to a syrup and diluted with a half
saturated NaCI solution (100 ml) and extracted with Et20 (3 x 50 ml). The combined organic
phases were dried with Na2S04, and concentrated to afford a reddish-brown oil (5.34 g, 18.3
mmol). This intermediate azide product was used without purification in the subsequent
Staudinger reduction. After dissolving the intermediate azide product (2.3 g, 7.9 mmol) in
toluene (45 ml), resin-bound triphenyl phosphine (3.3 g, ~10.0 mmol) was added at rt. The
mixture was stirred for 10 min at rt until gas evolution steadied and was heated to 90 °C for 20
h. Additional resin-bound triphenyl phosphine was added (0.5 g), until consumption of the
starting material was apparent by TLC. After cooling to rt, the phosphine resin was removed by
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vacuum filtration. The filtrate was concentrated and purified by flash column chromatography
on silica (elution: 30% to 100% EtOAc in hexane) to afford product 8 (0.88 g, 36% yield, 3 steps)
as a colorless solid and 9 (0.44 g, 19% yield, 3 steps) as a light yellow oil:
8: mp 133 °C; TLC (60% EtOAc in hexane), R/: 0.15 (KMn04); [a]D25 = -63.2° (c = 2.02, CH2CI2); IR
(film) 3022, 2948, 2872, 1684,1559, 1361, 1265, 1185, 1048, 934, 760 cm"1; JH NMR (400MHz,
C0CI3) 7.37 (m, 3H), 7.29 (m, 2H), 6.25 (s, 1H, C8H), 4.49 (m, 1H), 4.31 (m, 1H), 4.28 (d, J = 19.5
Hz, 1H), 4.12 (dd, J = 19.9, 3.9 Hz, 1H), 4.04 (t, J = 9 .0 ,1H, C6H), 3.83 (s, 3H); 13C NMR (100 MHz,
CDCI3) 6 166.0, 161.3, 136.9, 129.6, 128.9, 126.8, 90.2, 65.7, 55.1, 54.1, 53.6; Exact mass calcd
for C13H14N20 3Na [M+Na]+, 269.0897. Found 269.0892.
9: TLC (60% EtOAc in hexane), Rf: 0.20 (KMn04); [a]D25 - -107° (c = 2.30, CH2CI2); IR (film) 2993,
2950, 2892,1704,1438,1338,1315,1224,1113,1011, 850, 769 cm"1; JH NMR (400 MHz, CDCI3)
7.50 (m, 3H), 7.40 (m, 2H), 6.50 (s, 1H, C8H), 4.49 (dd, obs triplet, J * 6.6 Hz, 1H), 4.37 (m, 1H),
4.23 (s, 2H), 3.88 (t, J = 9.0 Hz, 1H, C6H), 3.76 (s, 3H); 13C NMR (100 MHz, CDCI3) 6 165.4, 158.6,
138.2, 129.3, 128.8, 126.5, 88.9, 69.4, 54.3, 53.8, 52,2; Exact mass calcd for C13H14N20 3Na
[M+Naf, 269.0897. Found 269.0901.

NaOMe
MeOH
76% yield
dr 95:5
Cycloadduct 13. To a solution of compound 8 (40.4 mg, 0.25 mmol) in methanol (2.00 mL)
under nitrogen was added salicaldehyde 10 (57.1 mg, 0.23 mmol) and sodium methoxide (0.37
mL, 2M, 0.75 mmol). The reaction vessel was fitted with a reflux condenser and heated to 65 °C.
After stirring at reflux for 21 h, the mixture was cooled to 23 °C, diluted with sat. aqueous NH4CI
and extracted with EtOAc (4 x 15 mL). The combined organic layers were washed with brine,
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dried with sodium sulfate, and concentrated in vacuo. The unpurified product was a single
diastereomer as judged by *H NMR spectroscopy. Purification by flash chromatography on silica
gel (elution: 20% to 60% EtOAc in hexane) afforded product 13 (68.7 mg, 76% yield) as a
colorless amorphous solid: TLC (40% EtOAc in hexane), Rf: 0.40 (CAM); [a]D25 = -75.3° (c = 0.77,
MeOH); IR (film) 2948, 2865, 1691, 1633,1490,1289 cm-1; XH NMR (400 MHz, CDCI3) 7.38-7.35
(m, 3H), 7.32-7.28 (m, 3H), 7.18 (t, J = 7.4 Hz, 1H), 7.05 (t, J = 7.4 Hz, 1H), 6.97 (d, J = 7.8 Hz, 1H),
6.26 (s, 1H), 4.51 (d, J = 9.3 Hz), 4.06 (dd, J = 11.7, 3.9 Hz, 1H), 4.02 (d, J = 9.4 Hz, 1H), 3.63 (s,
3H), 3.49 (d, J - 14.9 Hz, 1H), 3.42 (d, J = 14.9 Hz, 1H), 3.28 (t, J = 11.7 Hz, 1H), 2.77 (m, 1H), 2.35
(dd, J = 12.9, 9.8 Hz, 1H), 1.00 (dd, J = 12.9, 4.7 Hz, 1H); 13C NMR (100 MHz, CDCI3) 6 170.5,
168.9,159.0,136.4,132.5,131.3,129.2,128.5,127.5,126.3,123.9,120.2, 88.4, 70.7, 67.2, 66.0,
62.5, 54.5, 43.0, 36.6, 32.9); HRMS (ES+): Exact mass calcd for C23H22N20 4Na [M+Na]+, 413.1472.
Found 413.1470.
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CHAPTER III
SYNTHESIS OF MALBRANCHEAMIDE B
Introduction to Malbrancheamides:
The malbrancheamide family of diazabicyclic alkaloids was one of the most recently
discovered

groups

containing

a

[2.2.2]diazabicyclic

core.

Malbrancheamide

and

malbrancheamide B were originally isolated together from Malbranchea aurantiaca RRC1813 by
the Mata group in 2006 (Figure 3.1).1 These molecules represented the first members of the
alkaloid family to be isolated from a species not belonging to the genii of Aspergillus or
Penicillium and were the first to contain halogenation. Both of these molecules demonstrate
moderate biological activity as concentration-dependent calmodulin inhibitors of CaM-

Figure 3.1: The malbrancheamide family of alkaloids

malbrancheamide

premalbrancheamide

malbrancheamide B

(+)-malbrancheamide C

(-)-spiromalbramide

(+)-isomalbrancheamide C

(+)-isomalbrancheamide B
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dependent phosphodiesterase (PDE1).2 The Mata group later isolated an additional family
member, the nonhalogenated premalbrancheamide, from the same fungal species of
Malbranchea.

In 2011, Crews and coworkers identified (-)-spiromalbramide and (+)-

isomalbrancheamide

B, two

novel

graminicola UCSC 086937A.3

chlorinated

[2.2.2]diazabicycles

from

Malbranchea

The Crews group also isolated brominated analogues of

malbrancheamide B and (+)-isomalbrancheamide B upon fungal growth on bromine-enriched
medium.

These brominated

bicycles were

named (+)-malbrancheamide C and (+)-

alkaloids

the

isomalbrancheamide C.

Compared

to

related

like

stephacidins,

the

malbrancheamides

demonstrate little structural diversity. Structural features include a monoketopiperazine core,
bicycles of the more prevalent syn-conformation, and unsubstituted proline-derived rings. Only
spiromalbramide contains a spirocyclic ring fusion pattern resembling the spiro-oxindoles of the
marcfortines,

paraherquamides,

malbrancheamides

occur

and

mainly

in

notoamides.
their

indole

Structural variations
halogenation

between the

patterns.

All

the

malbrancheamides except premalbrancheamide exhibit either indole monohalogenation at the
C-5 or C-6 position or indole dihalogenation at both C-5 and C-6. This halogen substitution
feature is unique among the family of [2.2.2]diazabicycles and suggests a biogenic halogenation
pathway exclusive to the Malbranchea genus.

Investigation into the biosyntheses of the malbrancheamides has largely focused on the
timing of the indole halogenation and the sequence of diketopiperazine reduction to
monoketopiperazine core and intramolecular hetero-Diels-Alder (IMDA).4 The first proposal for
a biosynthesis of the malbrancheamides began with the condensation of L-tryptophan, Lproline, and dimethylallyl pyrophosphate (DMAPP) to deoxybrevianamide E (Scheme 3.1). At
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this point oxidation to either the reactive azadiene intermediate 5-hydroxypyrazin-2(lM)-one or
its carbonyl-reduced

analog would

allow the

IMDA to

keto-premalbrancheamide or

premalbrancheamide respectively. In the event that IMDA occurs prior to carbonyl reduction,
keto-premalbrancheamide would then be reduced to premalbrancheamide, which would in turn
lead to two successive halogenations, first to malbrancheamide B, then to malbrancheamide.
Precursor incorporation studies with doubly 13C-labeled premalbrancheamide and ketopremalbrancheamide by the Williams group showed that of the two potential precursors, only
13C-labeled premalbrancheamide is incorporated into malbrancheamide B by Malbranchea
aurantiaca.

This observation suggests that carbonyl reduction precedes [4+2] cycloaddition

which is followed by indole chlorination to malbrancheamide B and malbrancheamide.
Scheme 3.1: A proposed unified biosynthesis of the malbrancheamides

[>-C02H

N
H
H
deoxybrevianamide E

H

H '
a, X = 0
b, X * H2

H
IMDA

halogenase

keto-premalbrancheamide

premalbrancheamide

H
halogenase

malbrancheamide

48

malbrancheamide B

Previous Syntheses:
In a 2008

report,

Williams

and

coworkers

reported

the

first

synthesis of

malbrancheamide.5 At the time, the absolute structural configuration of malbrancheamide B
was unknown and as a result the authors chose to target three molecules through parallel
syntheses. The first target for synthesis was the known dihalogenated malbrancheamide. The
authors recognized that malbrancheamide B was halogenated at either the indole 5- or 6position.

To establish the configuration of the monohalogenated malbrancheamide B, the

authors chose to synthesize both 5- and 6-chloroindoles for comparison with natural samples.
These syntheses began by building around indoles which could be easily halogenated in
the 5- or 6-position. The three varieties of chlorinated indoles were functionalized with reverse
prenyl groups at the 2-position of the ring system (Scheme 3.2). These reverse-prenylated
indoles were then converted to gramines, which in turn were converted into their
corresponding tryptophan derivatives and Boc-protected at the free amine moiety. Ester
hydrolysis led to the formation of tryptophan-derived acids (Scheme 3.3).

Having already

incorporated tryptophan and isoprene-derived units into the hetero-Diels-Alder precursor, the
sole remaining component required for a biomimetic approach was a proline-derived unit. To
Scheme 3.2: Synthetic scheme of reverse prenylated tryptophan derivatives
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H
X,Y=CI or H

this end, the tryptophan-derived acids were coupled with c/s-3-hydroxyproline ethyl ester and
deprotected,

allowing

immediate

cyclization

to

the

corresponding

diketopiperazines.

Dehydration of these products yielded the appropriate IMDA substrates, cyclization of which
gave a separable mixture of [2.2.2]diazaoctane bicycle diastereomers. Selective reduction of
these [2.2.2]bicycles with Dibal-H produced the three desired targets at which point the
absolute structure of malbrancheamide B was verified by comparison to synthetic material.
These biomimetic syntheses are elegant and concise, but possess the obvious drawback of
intercepting an achiral azadiene IMDA substrate resulting in a racemic mixture of
[2.2.2]diazaoctane bicyclic adducts.
Scheme 3.3: Formation of [2.2.2]diazabicycle

Simpkins and coworkers reported the enantioselective total synthesis of entmalbrancheamide B in 2009.6 Model studies from the Simpkins lab revealed that the [2.2.2]diazabicyclic core could be accessed with desired stereoselectively by cation olefin cyclization
from a suitable diketopiperazine precursor via a-amido A/-acyliminium species intermediate.7 To
apply this novel cylization methodology, Simpkins elected to

initially target (-)-enT-

malbrancheamide B, the unnatural stereoisomer, primarily because of the low cost of the
corresponding L-proline.
The Simpkins synthesis, much like the Williams synthesis, began from an indole nucleus;
the illustrated Boc-protected 6-chlorocarboxaldeyde was easily prepared from commercially
available materials (Scheme 3.4).6 Aldol addition of this formylated indole nucleus to a methyl
ester led to an alcoholic aldol adduct. Dehydration and saponification of this aldol product led
to the corresponding carboxylic acid which was then bonded to a prenylated proline derivative
via standard amino acid coupling. At this point, all three essential components of the natural
product, tryptophan, proline, and an isoprene unit, have been incorporated. Deprotection of
Scheme 3.4: Synthetic preparation of [2.2.2]diazaoctane-precursor
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Boc

the remaining protected enol with CBr4 in warm isopropyl alcohol delivered the key
diketopiperazine cyclization precursor necessary for the planned cation olefin cyclization. Upon
treatment with trimethylsilyl triflate, both the indole N-Boc protecting group was cleaved and
the [2.2.2]diazaoctane bicycle was formed in 4:1 mixture of epimers favoring the desired
product in 64% yield (Scheme 3.5). The product of reductive cleavage of the remaining BOM
protecting group was the same diketopiperazine bicycle made in Williams' malbrancheamide
synthesis. Following Williams' precedent, Simpkins employed a Dibal-H reduction to form (-)ent-malbrancheamide B.
Scheme 3.5: Cation olefin cyclization
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Previous research into [2.2.2]diazaoctane bicycles proved very useful in our pursuit of
malbrancheamide B. Having five strategies for installing the core structural motif at our disposal
and comparing the strengths and weaknesses of two excellent existing syntheses of our target
provided great insight. Inspired by the elegance of the biomimetic approach to establishing the
core structure, we chose to pursue a modified version of Williams' biomimetic approach in
which the incorporation of a chiral, nonracemic DKP-derived azadiene into the key IMDA would
impart diastereofacial bias.
Enantioselective Retrosynthesis:
We

constructed

the

restrosynthesis

of

our

enantioselective

route

to

(+)-

malbrancheamide B upon the effective demonstration of the directed domino reaction
sequence in a model system (Scheme 3.6). We anticipated that malbrancheamide B (1) could be
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accessed directly through palladium-catalyzed reduction o f oc,0-unsaturated aldehyde (2), an
intermediate which could be synthesized from domino reaction product 3 in a series of
functional group transformations aimed at removing the aminal directing group essential to the
domino sequence, but not present in the natural product. The domino sequence itself would be
the crux of our synthetic plan, establishing the core structure as previously discussed through
the one-pot aldol condensation, alkene isomerization, and intramolecular hetero-Diels-Alder
cyclization. Finally, we knew that the domino reaction substrates 4 and 5 could also be easily
prepared as the necessary preparatory precedent had almost entirely been established already.
Scheme 3.6: Retrosynthetic plan for enantioselective synthesis
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Methods, Results, and Total Enantioselective Synthesis:
In the forward sense, the first phase of the enantioselective synthesis was the
preparation of appropriate indole carboxaldehyde and DKP azadiene-precursor components
necessary for a domino reaction sequence. This necessitated a 4-step synthesis of the modified
chloroindole 4. These transformations mainly followed the procedures developed by Williams in
his biomimetic malbrancheamide synthesis and converted the commercially-available 6-
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chloroindole to our desired product (Scheme 3.7).5 No additional synthetic effort was necessary
in the preparation of an appropriate diketopiperazine since chiral, nonracemic phenylsubstituted DKP-precursor 5 was available in appreciable quantities following our model study
(Chapter II).

Scheme 3.7: Preparation of BOM-protected chloroindole 4
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The union of BOM-protected indole 4 and phenyl-functionalized DKP 5 was achieved on
exposure to basic conditions at reflux overnight (Scheme 3.8). The resulting domino reaction
sequence yielded an inseparable mixture of two diazabicyclic cycloadducts, 3a and 3b, in a 1:2
ratio as estimated by *H NMR spectroscopy with a combined yield of 85%. Not only did this
result confirm that the conditions employed were sufficient in affecting enolization in the DKP
substrate and isomerization in the aldol condensate, but it also suggested that the chiral phenyl
aminal on the DKP azadiene-precursor was effective in controlling facial accessibility in the
intermediate azadiene. At this time it was unclear whether the phenyl aminal exerted any
control over the facial accessibility of the alkene, but the 2:1 ratio of diastereomers observed
from this reaction was consistent with those of multiple racemic syntheses of the Williams
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Scheme 3.8: Domino cyclization in the enantioselective synthesis of malbrancheamide B
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group.2 The question of the aminal's role in facial preference would eventually be further
illuminated upon the completion of an analogous racemic domino reaction sequence. In spite of
the successful coupling of BOM-protected indole 4 and DKP 5 into a [2.2.2]diazabicycle, the
challenge of separating these cycloadducts proved overly difficult. Failure to isolate the major
diastereomeric product of the cycloaddition following multiple attempts at separation by
chromatography on silica gel forced the progression of the synthesis with the existing 1:2
mixture of diastereomers. Conversion of the diastereomeric mixture to a separable mixture of
diketopiperazines required one additional step. Initially, reaction with TMSI was employed as
the preferred method o f cleaving the cycloadducts' lactim methyl ether. Although this method
proved successful in derivatizing the lactim methyl ether with acceptable yields at first pass, the
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success of this method was inconsistent. As an alternative, exposing the diastereomers to mild
acidic conditions with equimolar quantities of TsOHH20 in CH2CI2 followed by basification
allowed for an identical conversion.

These acidic conditions affected the desired imine

hydrolysis more consistently than TMSI.

It was also observed through repetitions at room

temperature and 0°C that imine hydrolysis at higher temperature led to hydrolysis of the indolic
BOM group. This additional hydrolytic cleavage was avoided in the total synthesis as eventual
experience with both protected and unprotected materials revealed that preservation of the
BOM group led to improved solubility of later malbrancheamide precursors in most organic
solvents. The mixture of BOM-protected diketopiperazines 6a and 6b could be easily separated
by flash column chromatography on silica gel, but was achieved more efficiently by selective
precipitation of 6b through recrystallization of the mixture (60% yield).

The focus of our synthetic effort after establishing the diketopiperazine bicycle of 6b
was to establish the monoketopiperazine characteristic of the targeted natural product through
selective reduction of the tertiary amide.

Treatment with Dibal-H realized the desired

transformation and also revealed the benzyl amine and primary alcohol functionalities of 7 as a
result of the decomposition of the aminal auxiliary. At this point, we anticipated that four
remaining transformations would be required to complete the synthesis of malbrancheamide B.
As we envisioned utilizing the Horner-Wadsworth-Emmons olefination to affect a two carbon
extension of the chain opened upon Dibal-H treatment, it was necessary to oxide (S03pyr,
DMSO, Hiinig's base) alcohol 7 to the corresponding aldehyde 8.

The newly formed aldehyde 8 was an appropriate substrate for Horner-WadsworthEmmons olefination under soft enolization conditions8 and was coupled with phosphonamide 9
to form Weinreb amide 10 (Scheme 3.9). This reaction proved sufficient in extending the C l
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chain by the two carbons required to form the target's pyrrolidine ring. With the requisite chain
length installed, we next performed the reduction of amide 10 to corresponding a,(5unsaturated aldehyde 11 in order to set the stage for the planned cyclization strategy via
palladium-catalyzed reduction cascade.

Scheme 3.9: Anticipated HWE, reduction and hydrogenation to (+)-malbrancheamide B
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We hoped that upon exposure to H2 and Pd/C, aldehyde 11 would undergo several
transformations, ultimately resulting in the formation of malbrancheamide B. We anticipated
that BOM cleavage and hydrogenation of the a,|3-unsaturation would occur rapidly to form
intermediate 12. Saturated aldehyde 12 would itself undergo benzyl cleavage followed quickly
by cyclization to form (+)-malbrancheamide B (1). Initially, a small amount of the unsaturated
aldehyde 11 was used to probe the palladium reduction cascade. The crude

NMR spectral

data collected on this reaction product suggested that while the cascade was executing the
desired transformations, it was also effecting the removal of the C6-indole chlorination (Scheme
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3.10). Manipulations of the reaction conditions yielded no success in preserving the halogen.
While ineffective in completing the synthesis, these reactions did yield high resolution mass
spectrometry hits which supported our identification of the product as a des-chloro analog of
the targeted natural product.

Since loss of halogen proved unavoidable with catalytic

hydrogenation, we returned to aldehyde 8 and pursued an alternative reductive strategy for
completing the synthesis.

Scheme 3.10: Observed hydrogenation of 11 to premalbrancheamide
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Our experience working through the first attempted endgame informed us that
aldehyde 8 was suitable for extension through Horner-Wadsworth-Emmons. Since the main
advantage of Weinreb amide was the ease with which it could be converted to the a,(3unsaturated aldehyde, we chose to replace phosphonamide 9 for phosphonacetate 14. This
revised Horner-Wadsworth-Emmons led to the formation of a,{3-unsaturated methyl ester 15
(Scheme 3.11).

We anticipated that reduction of the a,(3~unsaturation in 15 would allow

subsequent cyclization to a pyrollidine ring. Sodium borohydride was selected to perform this
1,4-hydride reduction and proved competent, but at first attempt led to a 2:1 formation of
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Scheme 3.11: Amended route for the completion of (+)-malbrancheamide B
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allylic alcohol 16 over the desired saturated alcohol 17. Unsatisfied with this ratio of products,
further effort was devoted to finding preferable conditions and eventually the formation of
allylic alcohol was minimized. Under these optimized conditions, saturated alcohol 17 could be
isolated in 58% yield.

Our supply of the desired alcohol was supplemented by a diimide

reduction of the allylic alcohol converted undesired byproduct 16 to 17.
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With an extended C l chain in hand, our synthetic focus transitioned to achieving the
cyclization forming the pyrollidine ring. To complete this transformation, the primary saturated
alcohol 17 was first activated through mesylation. We had anticipated that the displacement of
this mesylate by the non-bonding pair of electrons o f the benzyl amine in an intramolecular Nalkylatron would happen at room temperature, but it turned out that the ambient temperature
was insufficient to drive this change. The mesylate was heated to 120 °C in a sealed tube with
toluene in order to achieve /V-alkylation and form the desired quaternary salt 18.

After

formation of 18 was completed, Kl and triethylamine were added to mixture, the tube was
returned to heat (120°C) for 20 hours, completing the dealkylation o f the benzyl functionality.
Finally, (+)-malbrancheamide B (1) was formed through the deprotection of the indole using the
mild TsOH H20 developed previously.

Racemic Retrosynthesis:
Having completed the total enantioselective synthesis of (+)-malbrancheamide B, we
were pleased with the facial selectivity of our IMDA cyclization and wanted to demonstrate the
brevity with which a racemic synthesis using the domino reaction sequence could be achieved.
The retrosynthesis built around this racemic domino reaction sequence involved only four
transformations (Scheme 3.12). In the forward sense we planned to couple the indole

Scheme 3.12: Retrosynthetic plan for racemic synthesis
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dieneophile 4 to an achiral diketopiperazine diene-precursor 19, then convert the resulting
cycloadduct to the diketopiperazine analog 19, which could be deprotected and, following
removal of the BOM-group, directly reduced using published precedent to the racemic natural
product.

M ethods, Results, and Formal Racemic Synthesis:
The BOM-protected chloroindole 4 was prepared in previous synthetic work leaving only
the synthesis of the achiral diketopiperazine demanded by the planned domino sequence. This
simplified alternative to the diene-precursor used in our enantioselective synthesis was
prepared in only 3 steps from proline methyl ester with a single chromatographic separation in
80% yield. This DKP substrate 20 was then coupled to chloroindole 4 under the same basic
conditions employed in all our other domino reactions.

The anticipated result of the racemic domino reaction sequence were IMDA
cycloadducts 21a and 21b, racemic cycloadducts resulting from the achiral nature of the
intermediate formed (Scheme 3.13). Unlike in any other domino reaction sequence however,
the diketopiperazine 21c was also consistently observed as a product of this reaction. The
presence of this third, unexpected product suggests that in addition to the envisioned domino
pathway, the lactim functionality of 21b was consistently and selectively hydrolyzing to the
diketopiperazine. The yield o f these three products was nearly quantitative and the ratio of synconfigured cycloadducts 21b and the derived DKP 21c to anti-configured product cycloadduct
21a, was 2.3:1 as judged by JH NMR spectroscopy.

This result meant that since the syn-

configured cycloadduct was hydrolyzing exclusively, both 21b and 21c could be advanced
toward the similarly syn-configured malbrancheamide B.
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Scheme 3.13: Racemic domino reaction sequence towards malbrancheamide B
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Satisfied that the results of the domino sequence had been thoroughly accounted for,
we used the chemistry established in our enantioselective synthesis of malbrancheamide B to
convert both racemic syn-configured cycloadducts to oxo-malbrancheamide B (22) under mild
acidic conditions (Figure 3.14). In 21b, this involved the deprotection of both the lactim Omethyl ether and the BOM-group on the indole, and in 21c, which had already been converted
from lactim ether to DKP, the acidic conditions only served to cleave the BOM functionality.
These two reactions proved reliable in synthesizing oxo-malbrancheamide B (87% from 21b;
61% from 21c), and given that this product was the penultimate precursor to the
monoketopiperazine natural product in Williams' synthesis, we felt content with the completion
of a formal synthesis.5
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Figure 3.14: Endgame of racemic synthesis
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Conclusions:
The total enantioselective of (+)-malbrancheamide B and an analogous racemic
synthesis are reported. In both cases, the core [2.2.2]diazabicycle of the natural product was
established via domino reaction sequence involving aldol condensation, isomerization, and
IMDA.

In the case of the enantioselective synthesis, a chiral aminal auxiliary on the IMDA-

precursor introduced via a chiral, non-racemic DKP diene-precursor enforced complete
diastereofacial control over the cycloaddition.
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Experimental Section:
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Chloroindole 4. Oxalyl chloride (1.00 mL) was added to DMF (0.95 mL) and CH2CI2 (31 mL) at CfC
and the solution was allowed to stir for 15 minutes at CfC. 6-Chloro-2-(2-methylbut-3-en-2-yl)lH-indole-3-carbaldehyde5(1.641 g, 7.47 mmol) was dissolved in CH2CI2 (21 mL) and transferred
to the oxalyl chloride solution over 2 min via syringe. The reaction mixture was allowed to stir at
CfC for 5 min and the cooling bath was removed. After stirring 1.5 h at rt, the mixture was
concentrated to a volume of ~5 mL and THF (10 mL), NaOH (10 mL), and H20 (10 mL) were
added. The biphasic mixture was stirred rapidly for 2 h, Et20 was added (15 mL) and the organic
layer removed. The aqueous layer was extracted with additional Et20 (3 x 15 mL). The combined
organic layers were washed with brine, dried (Na2S04), and concentrated in vacuo.
Recrystallization (MeOH/toluene) of the white powder afforded l “((benzyloxy)methyl)-6-chloro2-(2-methylbut-3-en-2-yl)-lH-indole-3-carbaldehyde (910 mg, 49% yield) as colorless needles:
mp 227 °C; TLC (10% EtOAc in hexane), Rf: 0.40 (CAM); IR (KBr pellet) 1628, 1577, 1457, 1378,
1352, 1294, 1179, 1147, 1102, 1061, 1104, 964, 922 cm"1; XH NMR (400 MHz, CDCI3) 10.45 (s,
1H), 8.34 (s, 1H), 8.28 (d, J = 8.6 Hz, 1H), 7.35 (d, J = 1.6 Hz, 1H), 7.24 (dd, J = 8.6, 2.0 Hz, 1H),
6.22 (dd, J = 17.6, 10.6 Hz, 1H), 5.32 (d, J = 2.0 Hz, 1H), 5.29 (d, J = 8.6 Hz, 1H), 1.73 (s, 6H); 13C
NMR (100 MHz, MeOD) 210.2, 188.7, 159.0, 147.5, 137.1, 130.1, 126.9, 124.2, 123.8, 113.5,
112.7, 41.4, 30.8, 29.5 6. Exact mass calcd for C14H14CINONa[M+Na]+, 270.0656. Found
270.0656.

To a dry flask was added NaH (57-63% disp. on oil, 71.2 mg, ca. 1.75 mmol) and DMF (1.6 mL).
The reaction vessel was cooled to 0 °C and l-((benzyloxy)methyl)-6-chloro-2-(2-methylbut-3-en64

2-yl)-lH-indole-3-carbaldehyde (141.0 mg, 0.569 mmol) was added as a solid in three portions
(gas evolution). The reaction mixture was stirred for 5 min, and then benzyl chloromethyl ether
(tech grade 75%, 0.471mL, 3.39 mmol) and tetrabutyl ammonium iodide (43.7 mg) were added.
The mixture was brought to room temperature over 1 h while stirring. The reaction mixture was
diluted with saturated aqueous NH4C1 and extracted with EtOAc (4 x 10 ml). The combined
organic portions were washed with brine, dried (Na2S04), and concentrated in vacuo. The
resulting residue was purified by flash chromatography on silica gel (elution: 15% to 30% EtOAc
in hexane gradient) to afford the protected indole 4 (185.2 mg, 88% yield) as a light yellow oil:
TIC (20% EtOAc in hexane), R/: 0.45 (CAM); IR (film) 1642, 1608,1578,1507,1474,1414, 1374,
1333, 1215,1153, 1133 cm"1;

NMR (400 MHz, CDCI3) 10.66 (s, 1H), 8.43 (d, J = 9.0 Hz, 1H),

7.42-7.23 (m, 7H), 6.22 (dd, J = 17.2,10.6 Hz, 1H), 5.55 (s, 2H), 5.12 (d, J = 10.6 Hz, 1H), 5.01 (d, J
~ 17.2 Hz, 1H), 4.58 (s, 2H), 1.73 (s, 6H); 13C NMR (100 MHz, CDCI3) 6 188.4,154.0,146.3,138.0,
136.3, 129.9, 128.7, 128.5, 128.4, 128.1, 124.7, 123.8, 123.7, 117.4, 112.9, 110.2, 73.5, 70.5,
42,0, 30.7. Exact mass calcd for C22H22CIN02Na{M+Nar, 390.1231. Found 390.1232.
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Cycloadduct 3a, 3b. To diketopiperazine 5 (0.3 mmol) in methanol (1.5 mL, degassed with
nitrogen) at rt was added chloroindole 4 (0.4 mmol) and a freshly prepared solution of sodium
methoxide (1 mmol, 0.5 mL, 2.0 M). The reaction mixture was heated to 65 °C for 22 h. After
cooling to rt, the reaction mixture was diluted with sat. aqueous NH4CI (10 mL) and extracted
with EtOAc (3 x 10 mL). The combined organic layers were washed with brine (10 mL), dried
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(Na2S04), filtered and concentrated in vacuo.

The unpurified product was a 2:1 ratio of

diastereomers as judged by 1H NMR spectroscopy.

The product was purified by flash

chromatography on silica gel (elution: 0% to 45% EtOAc in hexanes) to afford products 3a and
3b (combined 255.1 mg, 85% yield) as a yellow oil: TLC (20% EtOAc in hexane) Rf - 0.20 (CAM);
[a]D25 = -8.8° (c = 0.77, CHCI3); IR (film) 1698, 1644, 1475, 1411, 1361, 1311, 1261, 1203, 1066,
885 cm-1; *H NMR (400MHz, CDCI3) 7.44 (d, J = 8.2 Hz, 0.5H), 7.40 (d, J = 8.2 Hz, 1H), 7.39-7.30
(m, 20H), 7.26-7.23 (m, 2H), 7.19 (d, J = 1.6 Hz, 1H), 7.17 (d, J = 1.8 Hz, 2H), 7.10 (dd, J = 8.2,1.6
Hz, 2H), 7.06 (dd, J = 8.4, 1.6 Hz, 1H), 6.27 (s, 0.5H), 6.19 (s, 1H), 5.66-5.47 (m, 4H), 4.63-4.48
(m, 6.5H), 4.13 (d, J = 9.4 Hz, 0.5H), 4.12 (d, J = 9.8 Hz, 1H), 3.98 (d, J = 16.4 Hz, 1H), 3.86 (s, 3H),
3.76 (s, 1.5H), 3.28 (d, J = 17.2 Hz, 0.5H), 3.14 (d, J = 16.4 Hz, 1H), 2.54 (dd, J = 10.0, 3.7 Hz,
0.5H), 2.45 (dd, J = 10.0, 5.3 Hz, 1H), 2.38 (dd, J = 13.1, 10.0 Hz, 1H), 2.21 (dd, J = 13.1, 5.3 Hz,
1H), 2.17 (s,lH), 2.07 (dd, J = 12.9,10.2 Hz, 1H), 1.96 (dd, J = 12.9, 3.9 Hz, 1H), 1.59 (s, 1H), 1.48
(s, 3H), 1.44 (s, 1.5H), 1.32 (s, 3H), 1.27 (s, 1.5 H); 13C NMR (100 MHz, CDCI3) 6 171.4, 169.0,
129.2, 129.1, 128.5, 128.5, 128.5, 128.3, 128.0, 128.0, 128.0, 128.0, 126.4, 126.4, 125.6, 120.5,
120.4, 119.5, 119.5, 109.3, 88.7, 88.5, 73.1, 69.8, 67.6, 67.5, 66.8, 63.4, 63.2, 54.7, 54.4, 48.6,
36.8, 31.0, 28.1, 27.8, 27.6, 25.7, 23.8, 21.5; Exact mass calcd for Q sH ^C lN ^N a [M+Na]+,
618.2130. Found 618.2126.
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Diketopiperazine 6b. To a solution of compounds 3a and 3b (200 mg, 0.34 mmol) in CH2CI2
(33.5 mL) was added TsOH H20 (70 mg, 0.37 mmol) at 0°C. The reaction mixture was stirred at
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0°C for 1.5 h, and then sat. aqueous NaHC03 (2 mL) was added. The aqueous layer was
separated and extracted with EtOAc (4 x 10 mL). The unpurified product was a 1:2 ratio of
diastereomers as judged by

NMR spectroscopy. The unpurified residue (223.7 mg) was

dissolved in toluene (30 mL) and heated to 110°C. After 19 h, heat was removed, and the
solution was concentrated in vacuo. The residue was purified by recrystallization from 25%
EtOAc in hexane to afford product 6b (127 mg, 65% yield) as a colorless amorphous solid: TLC
(40% EtOAc in hexane) R/0.20 (CAM); [a]D25= -2.7 (c 0.48, MeOH); IR (KBr pellet) 1721, 1690,
1495, 1474, 1453, 1406, 1370, 1311, 1241, 1204, 1109, 1071, 929, 914, 881 cm '1; 2H NMR (400
MHz, CDCI3) 7.38-7.31 (m, 11H), 7.18 (d, J = 1.6 Hz, 1H), 7.08 (dd, J = 8.2, 2.0 Hz, 1H), 6.42 (s,
1H), 6.22 (s, 1H), 5.55 (d, J = 10.9 Hz, 1H), 5.52 (d, J = 11.3 Hz, 1H), 4.77 (d, J = 9.4 Hz, 1H), 4.58
(d, J = 11.7 Hz, 1H), 4.51 (d, J = 11.7 Hz, 1H), 4.14 (d, J = 9.8 Hz, 1H), 3.78 (d, J = 15.6 Hz, 1H), 2.68
(t, J = 7.4 Hz, 1H), 2.66 (d, J = 15.6 Hz, 1H), 2.34 (m, J = 7.8 Hz, 2H), 1.49 (s, 3H), 1.32 (s, 3H); 13C
NMR (100 MHz, CDCI3)

6

171.5, 166.1, 140.5, 139.1, 136.3, 129.4, 128.6, 128.6, 128.2, 127.9,

126.5, 125.0, 120.8, 119.2, 109.6, 107.2, 89.3, 73.0, 70.0, 68.4, 65.1, 60.8, 50.6, 36.4, 29.9, 27.8,
25.0, 21.0; Exact mass calcd for C34H32CIN3 0 4Na [M + Na]+, 604.1973, found 604.1967.
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HO
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H 9 V - CHO

BOM
Aldehyde 8. To a solution of compound 6b (63 mg, 0.11 mmol) in toluene (1 mL) at 0°C was
added Dibal-H (2.10 mL, 1.0 M solution in toluene). The reaction was stirred for 0.5 h at 0°C, and
then EtOAc (2 mL), potassium sodium tartrate tetrahydrate (100 mg), and water (2 mL) were
successively added. The biphasic mixture was stirred rapidly for 1 h, and the organic layer was
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removed. The aqueous layer was extracted with additional EtOAc (3 x 10 mL). The organic layers
were combined, dried (Na2S04), and concentrated in vacuo. The unpurified product was a single
diastereomer as judged by 1H NMR spectroscopy. The residue was purified by flash
chromatography on silica gel (elution: 45-65% EtOAc in hexane) to afford the derived
intermediate aminoalcohol 7 (49 mg, 80% yield) as a yellow oil. Spectral data were in agreement
with published data.9 To a portion of aminoalcohol 7 (43 mg, 0.08 mmol) in CH2CI2 (1.5 mL) at
0°C was added DMSO (55 pL) and /Pr2NEt (100 pL, 0.57 mmol). To this solution was added
S03 pyridine (0.5 M, 450 pL). The solution was stirred for 30 min at 0°C and extracted with
EtOAc (3 x 10 mL). The organic layers were combined, washed with brine, dried (Na2S04), and
concentrated in vacuo. The residue was purified by flash chromatography on silica gel (elution:
35-100% EtOAc in hexane) to afford product

8

(39 mg, 92% yield) as a yellow oil: TLC (50%

EtOAc in hexane) R/0.25 (CAM); [a]D25= +20.9 (c 1.0, CH2CI2); IR (film) 1733, 1669, 1475, 1454,
1360, 1318, 1266, 1240, 1202, 1132, 1065, 882, 805, 738 cm '1; *H NMR (400 MHz, CDCI3) 10.23
(s, 1H), 7.43-7.18 (m, 11H), 7.06 (d, J = 8.2 Hz, 2H), 6.44 (s, 1H), 5.53 (s, 2H), 4.57 (s, 2H), 4.28 (d,
J = 12.9 Hz, 1H), 3.31 (d, J = 12.9 Hz, 1H), 3.23 (d, J = 10.9 Hz, 1H), 2.88 (d, J = 15.6 Hz, 1H), 2.80
(d, J = 15.2 Hz, 1H), 2.29-2.01 (m, 4H), 1.54 (s, 3H), 1.45 (s, 3H) 13C NMR (100 MHz, CDCI3)

6

198.9, 171.7, 141.2, 138.8, 137.7, 136.7, 128.6, 128.4, 128.4, 128.3 128.2, 127.9, 127.3, 125.0,
120.8, 118.8, 109.7, 106.6, 77.2, 73.0, 70.1, 66.5, 59.4, 59.2, 55.1, 47.3, 35.2, 30.1, 29.5, 28.8,
22.5; Exact mass calcd for C34H34ClN30 3Na [M + Na]+, 590.2181, found 590.2184.
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Weinreb Amide 10. To a solution of compound 8 (39 mg, 0.069 mmol) in acetonitrile (3.8 mL)
was added phosphonamide 9 (34 mg, 0.14 mmol), LiCI (23 mg, 0.54 mmol), and DBU (0.026 mL,
0.17 mmol). The solution was stirred at rt for 1 h, and then H20 (2 mL) was added. The aqueous
layer was separated and extracted with EtOAc (3 x 10 mL). The organic layers were combined,
washed with brine, dried (Na2S04), and concentrated in vacuo. The residue was purified by flash
chromatography on silica gel (elution: 60-80% EtOAc in hexane) to afford product 10 (27 mg,
60% yield) as a yellow oil: TLC (60% EtOAc in hexane) R/ 0.20 (CAM); [a ] D25 = +8.9 (c = 0.09,
CH2CI2); IR (film) 1682, 1629, 1472, 1455, 1418, 1374, 1313, 1241, 1204, 1131, 1061, 999, 882,
800, 753 cm-1; XH NMR (400 MHz, CDCI3) 7.52-7.13 (m, 14H), 7.05 (dd, J = 8.4, 1.8 Hz, 1H), 6.33
(s, 1H), 5.55 (s, 2H), 4.57 (d, J = 0.8 Hz, 2H), 4.28 (d, J = 13.7 Hz, 1H), 3.68 (s, 3H), 3.27 (s, 3H),
3.27 (d, J = 10.9 Hz, 1H), 3.13 (d, J = 13.3 Hz, 1H), 2.83 (q, J = 15.2 Hz, 2H), 2.30-2.25 (m, 2H),
2.10-2.04 (m, 2H), 1.58 (s, 3H), 1.43 (s, 3H); 13C NMR (100 MHz, CDCI3)

6

172.0, 143.2, 141.5,

138.9, 138.5, 136.8, 128.6, 128.4, 128.3, 128.2, 128.1, 128.0, 127.0, 125.1, 122.0, 120.8, 118.7,
109.8,106.8, 73.1, 70.2, 62.0, 61.9, 60.1, 59.3, 54.9, 47.8, 35.1, 35.0, 30.3, 30.2, 22.5; Exact mass
calcd for G ^ iC lN ^ N a [M + Na]+, 675.2709, found 675.2702.
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Premalbrancheamide. To a solution of compound 10 (26 mg, 0.39 mmol) in PhMe (1 mL) at
-78°C was added a solution of Dibal-H (1.0 M in PhMe, 0.20 mL). The solution was stirred for 1
h, and then MeOH (1 mL), HCI (1 mL), EtOAc (1 mL), and potassium sodium tartrate*4H20 (50
mg) was added. After an additional 1 h of stirring, the aqueous layer was separated and
extracted with EtOAc (3 x 10 mL). The organic layers were combined, dried (Na2S04), and
concentrated in vacuo. The residue was quickly purified by flash chromatography on silica gel
(elution: 40-100% EtOAc in hexanes) to afford product 11 (15.5 mg, 67% yield) as a light yellow
oil. Aldehyde 11 was unstable and prone to decomposition; accordingly, the product was used
immediately in the following reduction sequence. To a solution of compound 11 (7.0 mg, 0.015
mmol) in MeOH (1.0 mL) was added Pd/C (17 mg) at rt. The solution was sparged with H2. After
5 min, the H2 was stopped and Ar was bubbled through the solution. The suspension was
filtered through Celite and concentrated in vacuo to afford a mixture containing predominantly
premalbrancheamide (4.0 mg, 65% yield): TLC (80% EtOAc in hexane) R/ 0.25 (CAM). Spectral
data for premalbrancheamide were in agreement with published data.1011
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Methyl Ester 15. To a solution of compound 8 (110 mg, 0.19 mmol) in acetonitrile (10 mL) was
added trimethyl phosphonoacetate 14 (0.065 mL, 0.40 mmol), LiCI (67 mg, 1.60 mmol), and DBU
(0.075 mL, 0.50 mmol). The solution was stirred at rt for 1 h, and then H20 (2mL) was added.
The aqueous layer was separated and extracted with EtOAc (3 x 10 mL). The organic layers were
combined, washed with brine, dried (Na2S04), and concentrated in vacuo to give a 3:1 mixture of
E and Z isomers of 15 as shown by 1H NMR spectroscopy. The residue was purified by flash
chromatography on silica gel (elution: 40-100% EtOAc in hexane) to afford product 15 (110 mg,
91% yield) as a yellow oil: TLC (40% EtOAc in hexane) R/0.40 (CAM); [a]D25= +7.9 (c 2.4, CH2CI2);
IR (film) 1724, 1685, 1608, 1562, 1495, 1475, 1454, 1359, 1308, 1241, 1202, 1174, 1131, 1062,
882, 803, 740 cm"1;

NMR (400 MHz, CDCI3) 7.51 (d, J = 16.4 Hz, 1H), 7.38-7.18 (m, 12H), 7.05

(d, J = 8.2, 1H), 6.63 (d, J = 16.4 Hz, 1H), 5.55 (s, 2H), 4.60-4.54 (m, 2H), 4.25 (d, J = 12.9 Hz, 1H),
3.78 (s, 3H), 3.71 (s, 1H), 3.26 (d, J = 10.9 Hz, 1H), 3.13 (d, J = 13.3 Hz, 1H), 2.89-2.81 (m, 2H),
2.25-2.05 (m, 4H), 1.58 (s, 3H), 1.43 (s, 3H); 13C NMR (100 MHz, CDCI3) 6 171.9, 166.8, 145.2,
141.3, 138.8, 138.3, 136.8, 128.6, 128.4, 128.3, 128.3, 128.2, 128.1, 128.0, 127.9, 127.1, 125.0,
124.1, 120.8, 120.7, 118.8, 109.7, 106.8, 77.2, 73.0, 70.1, 61.6, 59.8, 59.3, 54.9, 51.7, 47.8, 35.1,
34.6,

30.3, 30.0, 24.3, 22.4; Exact mass calcd for C37H38ClN30 4Na [M + Na]+, 646.2443, found

646.2436.
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Saturated Alcohol 17. To a solution of compound 15 (36 mg, 0.059 mmol) in THF (1.0 mL) at 0°C
was added NaBH4 (24 mg, 0.64 mmol) and Lil (76 mg, 0.57 mmol). The solution was warmed to
rt, and additional NaBH4 and Lil (10 equivalents each) were added in three portions after
successive 12 h increments. After 48 h, sat. aqueous NH4CI (1 mL) was added. The aqueous layer
was separated and extracted with EtOAc (3 x 10 mL). The organic layers were combined, washed
with brine, dried (Na2S04), and concentrated in vacuo to give a 1:3 mixture of alcohols 16 and 17
as shown by *H NMR spectroscopy. The residue was purified by flash chromatography on silica
gel (elution: 50-100% EtOAc in hexanes) to afford product 17 (20 mg, 58% yield) as a white
solid: mp 92.7-94.2°C; TLC (60% EtOAc in hexane), R/0.15 (CAM); [a]D25 = +1.4 (c 0.85, CH2CI2);
IR (film) 1740, 1672, 1473, 1453, 1359, 1318, 1240, 1205, 1059, 882, 802, 746 cm-1; *H NMR
(400 MHz, CDCI3) 7.40-7.13 (m, 12H), 7.04 (d, J = 8.2 Hz, 1H), 6.56 (s, 1H), 5.54 (s, 2H), 4.56 (s,
2H), 4.27 (d, J = 12.9 Hz, 1H), 3.78-3.72 (m, 2H), 3.11 (d, J = 10.9 Hz, 1H), 3.06 (d, J = 12.5 Hz,
1H), 2.81 (d, J = 15.6, 1H), 2.76 (d, J = 15.2, 1H), 2.48 (s, 1H), 2.27 (dd, h = 13.3, J2 = 4.3 Hz, 1H),
2.20 (d, J = 11.3 Hz, 1H), 2.07-1.98 (m, 2H), 1.93 (d, J = 11.7, 2H), 1.88-1.83 (m, 2H), 1.52 (s, 3H),
1.44 (s, 3H); 13C NMR (100 MHz, CDCI3) 6 174.4, 141.6, 138.8, 138.5, 136.8, 128.6, 128.4, 128.3,
128.2, 127.9, 127.0, 125.1, 120.8, 118.7, 109.7, 106.8, 77.2, 73.1, 70.1, 62.7, 60.2, 59.6, 57.3,
54.5, 47.3, 35.1, 30.4, 30.2, 30.1, 26.9, 26.4, 22.3; Exact mass calcd for C36H4oCIN30 3 Na [M +
Na]+, 620.2650, found 620.2643. Alcohol 17 can also be prepared from 16 as follows. To a
solution of compound 16 (6.0 mg, 0.0092 mmol) in EtOH (0.4 mL) at rt was added 4methylbenzene sulfonhydrazide (2 mg, 0.010 mmol) and NaOAc (lmg, 0.010 mmol). The
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solution was heated to reflux, and additional portions (0.010 mmol) of sulfonhydrazide and
NaOAc were added after 2 h. After 6.5 h at reflux, heat was removed, and the solution was
concentrated in vacuo. Sat. aqueous Na2C03 (2 mL) and EtOAc (2 mL) were added to the residue,
and the aqueous layer was separated and extracted with additional EtOAc ( 3 x 5 mL). The
organic layers were combined, washed with brine, dried (Na2S04), and concentrated in vacuo.
The residue was purified by flash chromatography according to the above procedure to afford
17 (3.3 mg, 60% yield) as a white solid.

1. i. MsCI, pyr
ii. PhMe 120°C
2. Kl, NEt3, PhMe, 120°C
3. i. TsOH H20;
ii. NaH0O3; PhMe, A

(+)-1
HO

Cl

Malbrancheamide B (1). To a solution of compound 17 (24 mg, 0.040 mmol) in CH2CI2 (0.4 mL)
at 0°C was added pyridine (6.3 pL, 0.079 mmol) and MsCI (3.4 pL, 0.043 mmol). The solution was
allowed to warm to rt with stirring, and additional portions of MsCI (3.4 pL, 0.043 mmol) were
added every 3 h. After a total of 12 h, sat. aq. NaHC03 (2 mL) was added. The aqueous layer was
separated and extracted with EtOAc (3 x 10 mL). The organic layers were combined, washed
with brine, dried (Na2S04), and concentrated in vacuo. The resulting residue (22 mg) was
dissolved in toluene (2 mL) and heated to 125°C in a sealed tube with stirring. After 10 h, heat
was removed, and the solution was concentrated in vacuo. To a solution of the unpurified
residue (18 mg) in toluene (1.5 mL) was added Kl (6.0 mg, 0.035 mmol) and NEt3 (0.15 mL) in a
sealed tube. The solution was heated to 125°C and stirred for 20 h. After 20 h, heat was
removed, and the solution was concentrated in vacuo. To a solution of the unpurified residue
(13 mg) in CH2CI2 (2.6 mL) was added TsOHH20 (15.8 mg, 0.083 mmol) at 0°C. The solution was
allowed to warm to rt with stirring, and an additional portion of TsOH H20 (14 mg, 0.072 mmol)
73

was added after 2 h. After a total of 4 h, NaHC03 (2 mL) was added. The aqueous layer was
separated and extracted with EtOAc (4 x 10 mL). The organic layers were combined, washed
with brine, dried (Na2S04), and concentrated in vacuo. The product was purified by flash
chromatography on silica gel (elution: 0-10% MeOH in CHCI3) to afford product 1 (6.0 mg, 40%
yield) as an amorphous colorless solid: TLC (5% MeOH in CHCI3), R/0.50 (CAM); [cx]D25 = +25 (c
0.4, MeOH), Lit.12 [a]D= +50 (c 1, MeOH), Lit.613 (-)-l, [a]D= -36 (c 0.81, MeOH), Lit.14 [a]D= +28
(c 0.5, MeOH); HPLC trace and UV signature identical for both synthetic and an authentic natural
sample of 1; Mobile phase, gradient mixture of H20 + 0.1% TFA/MeCN, 1.0 mL/min; 0-10 min
20% MeCN, 10.01-20 min 20-50% MeCN); Phenomenex C18 Luna (250 mm x 4.6 mm x 5 |im),
retention time 15.17 min; UVX 230, 283 nm; IR (film) 1653,1465,1361,1319,1291,1253,1227,
1198,1131,1099,1059,1024, 904, 797 cm"1; Exact mass calcd for C2iH24CIN30[M+H]+, 370.1681,
found 370.1677. JH and 13C NMR spectral data for synthetic material both match the data for
the authentic sample and are in agreement with published data.15a,6,12b
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Cycloadducts 21a, 21b, 21c. To diketopiperazine 20 (18 mg, 0.11 mmol) in MeOH (0.1 mL,
degassed with nitrogen) at rt in a sealed tube was added 4 (20 mg, 0.05 mmol) and a freshly
prepared solution of NaOMe in MeOH (5 equiv, 0.3 mL, 5.0 M). The reaction vessel was heated
to 90°C (bath temperature) for 68 h. After cooling to rt, the reaction mixture was diluted with
sat. aqueous NH4CI (1 mL) and extracted with EtOAc ( 4 x 5 mL). The combined organic layers
were washed with brine (5 mL), dried (Na2S04), filtered and concentrated in vacuo to give a
1.7:1.0:2.9 mixture of cycloadducts 21a, 21b, and 21c as determined by JH NMR spectroscopy
on the unpurified mixture of products. The residue was purified by flash chromatography on
silica gel (elution: 0-5% MeOH in CHCI3) to afford products 21a (8.0 mg, 29% yield), 21b (6.0 mg,
22% yield), and 21c (13.0 mg, 48% yield).

21a: (light yellow oil) TLC (5% MeOH in CHCI3), R/0.55 (CAM); IR (film) 1685, 1633, 1476, 1419,
1354, 1324, 1260, 1205, 1179, 1092, 1077, 1055, 1001, 920, 886, 838, 799, 740, 702 cm-1; *H
NMR (400 MHz, CDCI3) 7.50 (d, J = 8.2 Hz, 1H), 7.38-7.30 (m, 5H), 7.19 (s, 1H), 7.10 (dd, J = 8.2,
1.6 Hz, 1H), 5.59 (d, J = 11.3 Hz, 1H), 5.53 (d, J = 11.3 Hz, 1H), 4.56 (d, J = 11.7 Hz, 1H), 4.50 (d, J =
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11.7 Hz, 1H), 3.91 (d, J = 17.6 Hz, 1H), 3.71 (s, 3H), 3.54-3.43 (m, 2H), 3.28 (d, J = 17.2 Hz, 1H),
2.71-2.64 (m, 1H), 2.41 (dd, J = 9.6, 4.1 Hz, 1H), 2.09-1.84 (m, 5H), 1.39 (s, 3H), 1.23 (s, 3H); 13C
NMR (100 MHz, CDCI3) 6 172.2, 170.9, 141.3, 139.3, 137.3, 128.8, 128.2, 128.1, 126.4, 120.6,
120.0, 109.5, 109.4, 73.3, 70.0, 66.8, 64.4, 54.6, 47.6, 43.8, 36.9, 34.5, 29.3, 27.9, 26.4, 24.9,
24.1; Exact mass calcd for C3oH32CIN303Na [M + Na]+, 540.2024, found 540.2017.

21b: (light yellow oil) TLC (5% MeOH in CHCI3), R/0.52 (CAM); IR (film) 1678, 1638, 1475, 1419,
1356,1310, 1265,1200, 1060, 882, 800, 736, 699 cm-1; *H NMR (400 MHz, CDCI3) 7.46 (d, J = 8.2
Hz, 1H), 7.39-7.30 (m, 5H), 7.18 (d, J = 1.6 Hz, 1H), 7.09 (dd, J = 8.2, 2.0 Hz, 1H), 5.55 (d, J = 5.1
Hz, 2H), 4.56 (d, J = 12.1 Hz, 1H), 4.48 (d, J = 12.1 Hz, 1H), 3.99 (d, J = 16.4 Hz, 1H), 3.80 (s, 3H),
3.51-3.33 (m, 2H), 3.08 (d, J = 16.4 Hz, 1H), 2.68-2.66 (m, 1H), 2.34 (dd, J = 10.4, 5.1 Hz, 1H),
2.04-1.92 (m, 4H), 1.83 (dd, J = 12.9, 5.1 Hz, 1H), 1.42 (s, 3H), 1.18 (s, 3H); 13C NMR (100 MHz,
CDCI3) 6 172.9,171.3,140.7, 139.1,137.1,128.5, 128.0, 127.9,125.7, 120.4, 119.6,109.9,109.2,

73.1, 69.7, 65.5, 64.3, 54.5, 54.5, 48.8, 43.4, 36.7, 32.8, 29.3, 27.8, 24.8, 21.4; Exact mass calcd
for C3oH32CIN303Na [M + Na]+, 540.2024, found 540.2017.

21c: (colorless solid) mp 224.2-225.6°C; TLC (5% MeOH in CHCI3), R/0.50 (CAM); IR (KBr pellet)
3199, 1691, 1475, 1455, 1199, 1098, 1058, 883, 811, 733, 697 cm-1; *H NMR (400 MHz, DMSO)
8.76 (s, 1H), 7.57 (s, 1H), 7.44 (d, J = 8.6 Hz, 1H), 7.37-7.28 (m, 5H), 7.10 (dd, J = 8.6, 2.0 Hz, 1H),
5.69 (d, J = 10.9 Hz, 1H), 5.64 (d, J = 10.9 Hz, 1H), 4.59 (s, 2H), 3.44 (d, J = 15.6 Hz, 1H), 3.35 (s,
1H), 3.33-3.23 (m, 1H), 2.72 (d, J = 16.0 Hz, 1H), 2.55-2.50 (m, 2H), 2.12-1.81 (m, 5H), 1.36 (s,
3H), 1.09 (s, 3H); 13C NMR (100 MHz, DMSO) 6 173.0, 168.2, 141.5, 138.6, 137.5, 128.3, 127.7,
127.7, 126.8, 125.0, 120.0, 119.1, 109.8, 107.2, 73.1, 69.0, 66.1, 58.9, 50.2, 43.6, 35.8, 30.5,
28.6, 27.1, 24.0, 23.6, 20.3; Exact mass calcd for C29H3oCIN303Na [M + Na]+, 526.1868, found
526.1862.
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Oxomalbrancheamide B (22). To a solution of compound 21b (6 mg, 0.012 mmol) in CH2CI2 (0.5
mL) at 0°C was added TsOHH20 (6 mg, 0.029 mmol). The solution was allowed to warm to rt
with stirring, and an additional portion of TsOH H20 (6 mg, 0.029 mmol) was added after 2 h.
After a total of 4 h, sat. aqueous NaHC03 (2 mL) was added. The aqueous layer was separated
and extracted with EtOAc (4 x 10 mL). The organic layers were combined, washed with brine,
dried (Na2S04), and concentrated in vacuo. The unpurified residue (4 mg) was dissolved in
toluene (1 mL) and heated to 125°C in a sealed tube with stirring. After 22 h, heat was removed,
and the solution was concentrated in vacuo. The residue was purified by flash chromatography
on silica gel (elution: 5% MeOH in CHCI3) to afford product 22 (3.0 mg, 61% yield). 22 was also
prepared from 21c as follows: to a solution of compound 21c (11 mg, 0.021 mmol) in CH2CI2(0.5
mL) at 0°C was added TsOH H20 (10 mg, 0.053 mmol). The solution was allowed to warm to rt
with stirring, and an additional portion of TsOH-H20 (10 mg, 0.053 mmol) was added after 2 h.
After a total of 4 h, sat. aqueous NaHC03 (2 mL) was added. The aqueous layer was separated
and extracted with EtOAc (4 x 10 mL). The organic layers were combined, washed with brine,
dried (Na2S04), and concentrated in vacuo. The unpurified residue (12.4 mg) was dissolved in
toluene (1 mL) and heated to 125°C in a sealed tube with stirring. After 17 h, heat was removed,
and the solution was concentrated in vacuo. The residue was purified by flash chromatography
on silica gel (elution: 5% MeOH in CHCI3) to afford product 22 (7.0 mg, 87% yield). Spectral data
were in agreement with published data.153
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APPENDIX
SUPPORTING INFORMATION FOR:
CHAPTER II:
General Information. All reactions were carried out under an atmosphere of nitrogen in flamedried or oven-dried glassware with magnetic stirring unless otherwise indicated. Acetonitrile,
THF, toluene, and Et20 were degassed with argon and purified by passage through a column of
molecular sieves and a bed of activated alumina.1 Dichloromethane was distilled from CaH2prior
to

use. All reagents were used as received unless otherwise noted.

Flash column

chromatography2 was performed using SiliCycle siliaflash P60 silica gel (230-400 mesh).
Analytical thin layer chromatography was performed on SiliCycle 60A glass plates. Visualization
was accomplished with UV light, anisaldehyde, eerie ammonium molybdate, potassium
permanganate, or ninhydrin, followed by heating. Film (or KBr pellet) infrared spectra were
recorded using a Digilab FTS 7000 FTIR spectrophotometer. Optical rotations were determined
on either a Perkin-Elmer 341 polarimeter at 25 °C. JH NMR spectra were recorded on a Varian
Mercury 400 (400 MHz) spectrometer and are reported in ppm using solvent as an internal
standard (CDCI3 at 7.26 ppm) or tetramethylsilane (0.00 ppm). Proton-decoupled 13CNMR
spectra were recorded on a Mercury 400 (100 MHz) spectrometer and are reported in ppm
using solvent as an internal standard (CDCI3 at 77.00 ppm). All compounds were judged to be
homogeneous (>95% purity) by JH and 13C NMR spectroscopy. Mass spectra data analysis was
obtained through positive electrospray ionization (w/ NaCI) on a Bruker 12 Tesla APEX-Qe
FTICR-MS with an Apollo II ion source. HPLC was performed on a Shimadzu Prominence with
LC20AT pumps and photodiode array detector.
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SUPPORTING INFORMATION FOR:
CHAPTER III:
General Information. All reactions were carried out under an atmosphere of nitrogen in flamedried or oven-dried glassware with magnetic stirring unless otherwise indicated. Acetonitrile,
THF, toluene, and Et20 were degassed with argon and purified by passage through a column of
molecular sieves and a bed of activated alumina.1 Dichloromethane was distilled from CaH2prior
to

use. All reagents were used as received unless otherwise noted.

Flash column

chromatography2 was performed using SiliCycle siliaflash P60 silica gel (230-400 mesh).
Analytical thin layer chromatography was performed on SiliCycle 60A glass plates. Visualization
was accomplished with UV light, anisaldehyde, eerie ammonium molybdate, potassium
permanganate, or ninhydrin, followed by heating. Film (or KBr pellet) infrared spectra were
recorded using a Digilab FTS 7000 FTIR spectrophotometer. Optical rotations were determined
on either a Perkin-Elmer 341 polarimeter at 25 °C. XH NMR spectra were recorded on a Varian
Mercury 400 (400 MHz) spectrometer and are reported in ppm using solvent as an internal
standard (CDCI3 at 7.26 ppm) or tetramethylsilane (0.00 ppm). Proton-decoupled 13CNMR
spectra were recorded on a Mercury 400 (100 MHz) spectrometer and are reported in ppm
using solvent as an internal standard (CDCI3 at 77.00 ppm). All compounds were judged to be
homogeneous (>95% purity) by aH and 13C NMR spectroscopy. Mass spectra data analysis was
obtained through positive electrospray ionization (w/ NaCI) on a Bruker 12 Tesla APEX-Qe
FTICR-MS with an Apollo II ion source. HPLC was performed on a Shimadzu Prominence with
LC20AT pumps and photodiode array detector.
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